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ABSTRACT OF DISSERTATION
HORMONAL MODULATION OF THE BEHAVIORAL EFFECTS OF TRIAZOLAM
There  is  accumulating  evidence  from  many  directions  indicating  that  gender 
plays a critical role in drug abuse.  Biological factors, including gonadal sex hormones, 
contribute  in  a  significant  although  incompletely  understood  manner,  to  gender 
differences in  drug abuse. Female sex hormones have been shown to affect  central 
nervous  system function  and modulate  the effects  of  drugs  of  abuse.  For  example, 
GABAA receptor  function is  positively  modulated by progesterone.  There is  evidence 
from preclinical in vitro and in vivo studies as well as some clinical research suggesting 
that  progesterone  and  its  metabolites  may  enhance  the  behavioral  effects  of 
benzodiazepines, which also serve as positive modulators of GABAA receptors. 
The three studies presented here utilize within subject designs to assess the role 
of  progesterone  on  the  discriminative  stimulus,  subjective,  performance  and 
cardiovascular  effects  of  triazolam,  a  short-acting  benzodiazepine,  in  healthy, 
premenopausal women. The first study examined the effect of menstrual cycle phase on 
the discriminative stimulus effects of triazolam (0.00, 0.06, 0.12 and 0.25 mg/70 kg). The 
results of this study indicated that when progesterone levels peak (mid luteal phase), the 
discriminative stimulus effects of triazolam (0.12 mg/70 kg) are enhanced. The second 
study examined the separate and combined effects of a range of acute doses of oral 
micronized progesterone (0, 100 and 200 mg) and oral triazolam (0.00, 0.12 and 0.25 
mg/70  kg)  on  the  subjective,  psychomotor  and  physiological  effects  of  these 
medications, tested under conditions of low circulating sex hormones. The results of this 
study indicated that progesterone alone has some short-acting, sedative-like effects and 
enhances the subjective and performance effects of triazolam.  The final study examined 
the effects of  progesterone (0 and 100 mg) on the discriminative stimulus effects of 
triazolam (0.00, 0.06, 0.12 and 0.25 mg/70 kg), also under conditions of low circulating 
sex hormones.  The results of this study indicated that the parent hormone progesterone 
does not appear to alter sensitivity to the discriminative stimulus effects of triazolam. 
Increases in  sensitivity  to triazolam in studies 1 and 2 may have been the result  of 
neuroactive progesterone metabolites (e.g., allopregnanolone, TH-DOC), although future 
studies will be required to further examine this possibility.  Taken together, these studies 
help clarify the manner in which the ovarian hormone progesterone and its metabolites 
modulate the behavioral effects of the benzodiazepines.
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CHAPTER 1
INTRODUCTION
BACKGROUND RESEARCH
There is increasing evidence that the functional effects of drugs differ  among 
men and women.  Greater numbers of men use and abuse illicit  drugs than women 
(SAMHSA, 2009).  However, there are marked differences between men and women in 
the  relative  risk  of  developing  dependence  on  sedative-hypnotic  drugs  (e.g., 
benzodiazepines).  After initiating sedative-hypnotic drug use, women are significantly 
more likely to develop problematic use patterns relative to their male counterparts, such 
that women may be nearly twice as likely to develop dependence on these compounds 
(Kandel et al., 1998; Anthony et al., 1994).  In addition, women are prescribed sedative-
hypnotic compounds at higher rates than men (Nomura et al., 2006; Howes et al., 1996; 
van der Waals et al., 1993; Wysowski & Baum, 1991), take the medications longer once 
prescribed (Geiselmann & Linden, 1991), and are more likely to use the medications for 
non-medical purposes (Simoni-Wastila et al., 2004).
Gender disparities are undoubtedly influenced by environmental variables (i.e., 
drug availability, socio-cultural variables); however, there is also evidence that gender 
differences may be biologically mediated, and perhaps influenced by ovarian hormones. 
Ovarian steroid  hormones,  such as  estradiol  and progesterone,  crucial  to  peripheral 
nervous  system  function  and  reproductive  health,  modulate  central  nervous  system 
(CNS) function.  The non-genomic CNS actions of these steroids are mediated through 
neuronal  receptor  mechanisms,  resulting in  rather  rapid  modulation  of  the  effects  of 
psychoactive compounds.  Although the neurosteroids progesterone and estradiol are 
present in men, the circulating blood levels are minimal and stable across time.  The 
plasma levels of these hormones vary as a function of menstrual cycle phase and are 
present  at  different  circulating  levels  in  women.   Since  the  receptor  mechanisms 
modulated by steroid hormones overlap with  those affected by drugs of  abuse,  it  is 
critical to investigate whether ovarian hormones influence the abuse liability of drugs in 
women.
Although several sex hormones modulate drug action, a systematic examination 
of  an  individual  ovarian  hormone  is  an  informative  and  productive  approach,  as  it 
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provides detailed information regarding the relative influence of a single hormone in the 
acute effects of a drug.  Therefore, the following series of studies focus on the effects of 
progesterone.
Progesterone and its primary metabolites, allopregnanolone, pregnanolone and 
TH-DOC,  modulate  neurotransmitter  activity  via  both  genomic  and  non-genomic 
mechanisms. The non-genomic effects of these neurosteroids include direct activation of 
neuronal  membrane-bound  receptors  and  the  rapid  modulation  of  several 
neurotransmitter  systems including GABA,  dopamine,  opiate,  glutamate and nicotinic 
acetylcholine  systems  (Pluchino  et  al.,  2006;  Lena  et  al.,  1993).   The  most  well-
characterized and perhaps most influential, of progesterone’s effects are those at the 
GABAA receptor complex.  Sedative-hypnotic drugs such as the benzodiazepines also 
produce  their  effects,  in  large  part,  via  modulation  of  GABAA receptors. 
Allopregnanolone,  TH-DOC,  and  pregnanolone  are  ligands  at  extracellular,  steroid-
specific  recognition  sites  on GABAA receptors,  with  affinities  that  are  comparable  to 
those  of  many  benzodiazepines  (Paul  &  Purdy,  1992;  Majewska  et  al.,  1986).   In 
addition, these neurosteroids dose-dependently increase the effects of benzodiazepines 
on  GABA-induced  Cl- currents,  indicating  that  there  is  a  receptor-level  interaction 
between benzodiazepines and neurosteroids (Paul & Purdy 1992; Bertz et al., 1995). 
The behavioral effects of these neurosteroids also overlap with those engendered by 
benzodiazepines.   Through  GABAA modulation,  neurosteroids  can  induce  anxiolytic, 
sedative and antiepileptic effects (Schumacher et al., 1989).
The effects of progesterone and its metabolites on receptor function have been 
linked  to  many  of  the  clinical  effects  of  the  hormone,  including  sedation,  memory 
impairment,  anxiolysis,  depression,  alcohol  dependence,  stress  reduction  and  anti-
seizure effects (Pisu & Serra, 2004; Rhodes et al., 2004; Schumacher & Robert, 2002; 
Rupprecht, 2003).  Elucidation of the neuropharmacological effects of progesterone may 
elucidate some of the biological-mediated underpinnings of gender differences in these 
conditions.
Because progesterone metabolites have a direct action at GABA receptor sites, it 
is hypothesized that progesterone may potentiate the behavioral effects of GABAergic 
drugs.  Preclinical studies have demonstrated such an effect.  For example, Grant and 
colleagues have conducted research using non-human primates (Macaca fascicularis) 
and have demonstrated that the discriminative stimulus effects of ethanol are sensitive 
to menstrual cycle phase, such that the ethanol generalization curve is shifted to the left 
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during  the  mid-luteal  phase of  the  menstrual  cycle  when  progesterone  levels  surge 
(Grant et al., 1997, Green et al., 1999).  In contrast, menstrual cycle mediation of the 
effects  of  GABAergic  drugs  in  women  has  not  been  consistently  reported.  The 
reinforcing and subjective effects of ethanol have been examined across three phases of 
the menstrual  cycle  (early  follicular,  late follicular,  luteal)  in  normally  cycling,  healthy 
women (Holdstock & de Wit, 2000).  These investigators found no changes in alcohol 
effects as a function of menstrual cycle phase.  The subjective and performance effects 
of  triazolam have  also  been  examined  across  three  phases  of  the  menstrual  cycle 
(follicular,  periovulatory,  and  luteal),  with  no  menstrual  cycle  modulation  reported 
(Rukstalis & de Wit, 1999).  It remains to be seen whether procedures that have been 
developed  to  examine  the  receptor-mediated  effects  of  drugs,  such  as  the  drug 
discrimination methodology (e.g., Kamien et al., 1993; Kelly et al., 2003; Colpaert, 1999) 
could be used to test the clinical neuropharmacology of progesterone in a more sensitive 
manner than has been possible using self-report and performance measures.
Sensitivity to the behavioral effects of benzodiazepines in women also may be 
more  consistent  when  levels  of  neurosteroids  are  directly  manipulated.   When 
administered as a pre-treatment, exogenous oral micronized progesterone enhanced the 
sedative,  memory  and  performance  effects  induced  by  oral  triazolam  in  post-
menopausal women (McAuley et al., 1995).  In addition, women taking oral birth control 
containing  both  progesterone  and  estradiol  were  more  sensitive  to  the  performance 
impairing  effects  of  alprazolam,  lorazepam,  and  triazolam  (Kroboth  et  al.,  1985). 
Hormone  pre-treatment  studies  have  many  methodological  advantages  over  other 
approaches.   When  a  hormone  pre-treatment  is  administered  when  endogenous 
hormones are at nadir levels (e.g., the early follicular phase), it allows for the controlled 
examination of the effects of the hormone.  In contrast, when drug effects are examined 
across the cycle, various hormone levels are in flux, making it difficult to apply a causal 
mechanism to a particular hormone.  In addition, pre-treatment studies allow for multiple 
doses of hormone to be tested and dose-response relationships established.  As such, it 
is  clear that  pre-treatment studies hold significant  potential  for examining the clinical 
neuropharmacology  of  progesterone  and  to  elucidate  potential  gender  differences in 
sensitivity to the effects of benzodiazepines.
The purpose of the following series of studies is to determine whether the ovarian 
hormone progesterone modulates the behavioral effects of the sedative drug triazolam 
using human laboratory methodologies.  The first study will determine if elevated levels 
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of  progesterone  during  the  mid  luteal  phase  of  the  menstrual  cycle  enhances  the 
discriminative stimulus effects of triazolam, as compared to nadir levels of progesterone 
during the early follicular phase (i.e., menstrual cycle modulation of the discriminative 
stimulus  effects  of  triazolam).   The second study will  examine the independent  and 
combined subjective and psychomotor effects of exogenous progesterone and triazolam 
in  healthy  adult  premenopausal  women.  The  third  study  will  examine  whether 
exogenous progesterone pretreatment modulates the discriminative stimulus effects of 
triazolam. 
RATIONALE
The purpose of Study 1 is to determine if  the behavioral effects, including the 
discriminative stimulus effects, of triazolam are modulated as a function of menstrual 
cycle phase.  Drug discrimination methodology is incorporated as a primary measure in 
this study because there is evidence that drug discrimination may be more sensitive to 
hormonal modulation and to the effects of drugs at the receptor level, than self-report 
measures  alone  (Lile  et  al.,  2007;  Kelly  et  al.,  2003).   It  is  hypothesized  that  the 
discriminative stimulus effects of triazolam will be enhanced during the mid-luteal phase, 
when  progesterone  levels  are  elevated,  relative  to  the  early  follicular  phase,  when 
progesterone  is  at  nadir  levels.   The  results  of  this  study  will  help  elucidate  the 
underpinnings of changes in acute drug effects across the menstrual cycle. However, 
given that several hormonal changes occur across the menstrual cycle, it is not possible 
to determine from these results if a specific hormone modulates the effect of triazolam. 
Instead, these results will provide indirect information about the relationship between the 
hormonal array present during specific phases of the menstrual cycle and the behavioral 
effects  of  triazolam.   Specifically,  this  study  will  not  reveal  if  the  potentiation  of  the 
discriminative  stimulus  effects  of  triazolam  during  the  mid-luteal  phase  reflects 
independent  or  combined  effects  of  progesterone  or  estradiol  modulation  of 
benzodiazepine effects, since both steroids are elevated during the mid-luteal phase. 
Similarly,  it  will  not  be  possible  to  determine  whether  menstrual  cycle  effects  are 
associated with acute or repeated exposure to elevated hormones. Thus, it is necessary 
to conduct pre-treatment studies to isolate and manipulate the effects of progesterone to 
determine  if  the  changes  in  triazolam  effects  during  the  mid-luteal  phase  are  due 
specifically to the acute presence of progesterone.
The  purpose  of  Study  2  is  to  test  the  behavioral  effects  of  several  dose 
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combinations  of  both  oral  progesterone and triazolam.   This  study  will  examine the 
separate and combined behavioral effects of progesterone and triazolam across a range 
of doses in order to evaluate the interactive effects of these two compounds.  As this is 
the  first  study  to  examine  the  independent  and  combined  effects  of  these  two 
medications, it is important to establish dose-response relationships. Clinically relevant 
doses of  progesterone  and  triazolam are  tested  in  that  the  progesterone doses will 
engender progesterone plasma levels that are consistent with those naturally occurring 
across the menstrual cycle (Chakmakjian & Zachariah, 1987; Sofuoglu et al., 2001; de 
Wit et al., 2001; Soderpalm et. al., 2004), and the triazolam doses are within the dose 
range recommended for therapeutics (Physician’s Desk Reference, 2006).  This study 
will extend the results of the first study by directly examining the effects of physiological 
doses of progesterone, alone and in combination with a dose range of triazolam.  It is 
hypothesized that progesterone will potentiate the effects of triazolam.
The purpose of  Study 3 is to utilize drug discrimination methodology to more 
precisely  examine  the  neuropharmacological  effects  of  progesterone,  alone  and 
combination with triazolam, as drug discrimination has been shown to be an effective 
tool  in  examining  pharmacological  changes  mediated  by  receptor-based  interactions 
(Colpaert, 1999; Kelly et al., 2003).  The results of Study 2 will inform the pretreatment  
dose  of  progesterone  to  be  used  in  Study  3.  It  is  hypothesized  that  progesterone 
pretreatment will potentiate the discriminative stimulus, and other behavioral effects of 
triazolam.
IMPLICATIONS
Overall,  understanding  the  mechanisms  by  which  neurosteroids  modulate 
neurotransmitters  systems  has  important  clinical  implications.   Neurosteroids, 
specifically  progesterone  metabolites,  modulate  several  behaviors  and  disease 
conditions,  as  variations  in  these  hormones  contribute  to  predisposing  or  protecting 
individuals from sleep disturbances, anxiety, depression, epilepsy, dementia, and post-
partum depression  (Bicikova  et  al.,  2000,  Ströhle  et  al.,  2003;  Romeo et  al.,  1993; 
Murialdo  et  al.,  2001;  McCoy  et  al.,  2003;  Rupprecht,  2003).   Not  only  are  these 
hormones  a  factor  in  individual  differences  in  disease  processes,  variation  in 
neurosteroid  levels  also  contributes  to  individual  differences  in  drug  effects.   For 
example, levels of endogenous progesterone metabolites have been correlated with the 
severity of ethanol tolerance and withdrawal, and the efficacy of anxiolytic medications 
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(Romeo et al.,  1996; 2000; Le Mellédo et al.,  2000; Brambilla et al., 2005; Ho et al.,  
2004).   As  hormones  rapidly  fluctuate  across  the  menstrual  cycle,  intra-individual 
differences in hormonal modulated drug effects are particularly evident in women.  For 
example,  hormonal  changes across  the cycle  can often  necessitate  modifications  in 
doses  of  anti-epileptics  (Reddy,  2009;  Herzog  et  al.,  2009;  Bäckström,  1976)  and 
anesthetics (Erden et al., 2005) to properly maintain the condition without adverse side 
effects.  As such, understanding the role of neurosteroids in drug modulation may lead to 
a greater understanding of gender and individual  differences in the effects of  certain 
drugs.  Taken together, elucidating the biological underpinnings of the gender differential 
observed in abuse and dependence liability may inform gender-specific drug prevention 
and treatment strategies.
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CHAPTER 2
STUDY 1: Modulation of the discriminative stimulus effects of triazolam across the 
menstrual cycle phase in healthy pre-menopausal women
INTRODUCTION
Progesterone is a positive modulator of the GABAA receptor complex, and its 
primary metabolites allopregnanolone, pregnanolone and TH-DOC function as ligands at 
extracellular steroid-specific recognition sites on GABAA receptors with affinities that are 
comparable to those of many benzodiazepines (Bertz et al., 1995; Paul & Purdy, 1992; 
Majewska,  1992;  Majewska et  al.,  1986).  Through GABAA modulation,  progesterone 
induces  behavioral  effects  similar  to  those  engendered  by  benzodiazepines  (e.g., 
anxiolysis, sedation and antiepileptic effects) (Frye, 2007; Rupprecht, 2003; Schumacher 
et al., 1989), and changes in progesterone levels across the menstrual cycle have been 
shown to modulate the behavioral  effects of  GABAergic drugs in pre-clinical  models. 
Grant and colleagues, for example, demonstrated that sensitivity to the discriminative-
stimulus effects of alcohol was enhanced in non-human primates during the mid-luteal 
phase of the menstrual cycle when progesterone levels are elevated compared to the 
follicular phase when progesterone levels are minimal (Grant et al., 1997, Green et al., 
1999).  In contrast,  few changes in  the reinforcing or  subjective effects of  ethanol  or 
triazolam have been reported across the menstrual cycle in normally cycling, healthy 
women  (Holdstock  &  de  Wit,  2000;  Rukstalis  &  de  Wit,  1999).   Inconsistencies  in 
menstrual  cycle  phase  modulation  of  sedative  drug  effects  across  studies  could  be 
related to differences in either species or methods used to assess drug effects. The 
current study addressed these inconsistencies by examining the discriminative stimulus 
effects of triazolam during the mid-luteal and early follicular phases of the menstrual 
cycle in normally cycling, healthy women. It was hypothesized that the discriminative 
stimulus effects of triazolam would be enhanced during the mid-luteal phase.
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METHOD
Participants
Healthy  pre-menopausal  women  were  recruited  through  local  newspaper 
advertisements and with flyers posted on a university campus.  All potential participants 
completed an initial telephone or internet-based screening questionnaire, and an on-site 
medical  evaluation  that  included  a  menstrual  history,  health  questionnaires,  blood 
chemistry and urinalysis.  Eligibility criteria included a minimum of 18 years of age, good 
health, reports of intermittent sedative drug use (e.g.,  alcohol) and regular menstrual 
cycles (monitored across two menstrual cycle phases prior to participation).  Exclusion 
criteria included significant medical history (e.g., cardiovascular, neurological, or major 
psychiatric illnesses,  including drug or alcohol  dependence),  regular  use of  drugs or 
alcohol,  other  than  nicotine  or  caffeine,  use  of  hormonally-based  contraceptives, 
pregnant  or  breastfeeding  status,  or  any  other  condition  that  for  which  triazolam 
administration would be contraindicated.  
Twenty participants met eligibility criteria and initiated the study. Eight participants 
withdrew  from  the  study  for  reasons  unrelated  to  the  study  protocol,  five  were 
discontinued from the study because they did not acquire the drug discrimination; data 
from  these  thirteen  participants  were  excluded  from  analyses.  Table  1.1  details 
demographic variables of participants who were unable to acquire the discrimination and 
the  participants  who successfully  acquired  the discrimination.  None  of  the  variables 
examined were consistently related to acquisition (either successful or unsuccessful) of 
the discrimination.  Seven volunteers completed the study. The participants ranged in 
age from 21 to 43 years (median = 30 years), in weight from 47 to 69 kg (median = 60  
kg), and drank 1 to 6 alcohol drinks per month (median = 2).  One participant was a 
smoker (mean of 10 cigarettes per day); however, she abstained from smoking for the 
duration of each session. 
Design
A double-blind, placebo-controlled, randomized within-subject design was used 
to assess the effects of menstrual cycle phase (early follicular and mid luteal), triazolam 
dose (training doses: 0.0, and 0.25 mg/70 kg, test doses: 0.06, 0.12 mg/70 kg), and time 
(assessments occurring pre-dose, 30, 60, 90, 120 and 150 minutes post-dose) on the 
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discriminative stimulus and other behavioral effects of triazolam. 
Participants were instructed to abstain from alcohol and all medications for 24 
hours and caffeine and food for 4 hours prior to their scheduled sessions.  At the begin-
ning of each session, participants were asked questions about medication use, sleep, 
food consumption and health status for the preceding 24 hours.  No sessions were can-
celled due to reports of atypical activities.  Participants then completed a field-sobriety 
test, provided a breath sample that was tested for alcohol use (Alco-Sensor III, Intoxi-
meters, Inc., St. Louis, MO) and provided a urine sample that was tested for amphetam-
ine, barbiturates, benzodiazepines, cocaine, marijuana, methadone, methamphetamine, 
MDMA, and opiates (E-Z Split Key Cup, ACON Laboratories, San Diego) and pregnancy 
(hCG One Step Pregnancy Test Device, Instant Technologies, Inc., Norfolk, VA). 
Assessments used to measure drug effects included a Drug Discrimination Task 
(post-dose only), Visual Analog (VAS) and Adjective Rating (ARS) Scales, Digit Symbol 
Substitution Task (DSST), and heart rate and blood pressure measurement (Sentry II, 
NBS Medical, Costa Mesa, CA).
Drugs
Doses of triazolam were prepared by the University of Kentucky Investigational 
Pharmacy.   Triazolam (0.00,  0.06,  0.12 and 0.25 mg/70 kg) was prepared in  size  0 
opaque capsules,  with cornstarch filler.   Placebo capsules contained only cornstarch 
filler.  Triazolam doses were delivered orally.
Assessment Tasks
 Drug-Discrimination Task
During this task, two circles labeled with a color code (i.e., “Red” and “Blue”) were 
displayed  on  the  computer  screen,  each  associated  with  a  training  dose  condition. 
Counters were displayed directly below the circles. A mouse controlled the location of a 
cursor on the screen, and mouse button presses with a cursor positioned on a circle 
increased  the  counter  associated  with  that  circle  according  to  a  fixed-interval  1-sec 
schedule. The cursor could alternate across the circles without any consequence under 
the  fixed-interval  schedule  (i.e.,  no  change-over-delay).  Up  to  60  points  could  be 
allocated across the two options. The dependent variable for this task was the percent 
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responding on the active drug-appropriate option.
Drug discrimination procedure
Sampling Phase
The sampling phase consisted of four sessions; each of the triazolam training 
doses (0.00 and 0.25 mg/70 kg) was administered on two sessions in an alternating 
pattern.  For every participant, the training doses were associated with a fixed color code 
throughout the study, with the color-dose combinations and order of presentation being 
randomized across participants.  Dose color was identified during drug administration, 
and participants were told to associate the effects of the dose with that color.  Sampling 
sessions were conducted without regard to menstrual cycle phase.
Control Phase
Training doses of triazolam (0.00, 0.25 mg/70 kg) were administered randomly 
under  double-blind  conditions,  and  participants  were  not  told  which  dose  was 
administered  until  after  the  last  assessment  of  a  session.  Acquisition  of  drug 
discrimination was established when ≥ 80% of responses were allocated to the drug-
appropriate stimulus during the last assessment of the session (150 minutes post-dose) 
for 5 consecutive sessions. If the acquisition criterion was not met within 15 sessions, 
participation ended.  Participants who met criteria did so within 5 to 15 sessions.  Control 
sessions  were  conducted  without  regard  to  menstrual  cycle  phase  and  occurred 
immediately following training sessions. 
Test Phase 
Test Phase sessions were identical to control sessions, except that both training 
and test (0.06 and 0.12 mg/70 kg) doses were presented, and sessions were scheduled 
only during specific phases of the menstrual cycle. Participants completed 6 sessions 
during the early  follicular  phase of  the menstrual  cycle  (days 1-7  following onset  of 
menses) and 6 sessions during the mid-luteal phase of their menstrual cycle (days 5-12 
following ovulation, as determined using daily urine assessments).  During each cycle 
phase, each training dose was administered once and each test dose was administered 
twice.  The order of menstrual cycle phase testing (i.e., whether test sessions began 
during  the  early  follicular  or  mid-luteal  phase)  was  randomized  and  varied  among 
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participants.  Sessions  were  scheduled  around  participants’  availability  within  each 
menstrual  cycle phase.  Because time during any particular  cycle phase was limited, 
participants completed the Test Phase across two or three consecutive cycle phases 
(i.e., across several months), such that some sessions were consecutive while others 
were separated by days or weeks. The length of time that elapsed between Control and 
Test Phase sessions varied depending on when participants’ next cycle phase occurred 
and ranged from zero days to three weeks.
After the final assessment on every session, participants were told whether a red 
dose, a blue dose, or a test dose had been administered.  On red and blue dose (i.e., 
training)  sessions,  participants  received  $0.04  per  point  accumulated  on  the  circle 
associated  with  the  dose  administered  on  that  session.   On  test  dose  sessions, 
participants received the average of earnings on training dose sessions, regardless of 
point distributions. 
VAS
Participants 9 rated items presented individually on the computer by marking a 
100-unit line anchored on the extremes by “Not At All” and “Extremely”.  Items included 
were: Stimulated, Sedated, Anxious, High, Confident, Hungry, Thirsty, Drug Effect, and 
Like Drug Effect.
ARS
The Adjective Rating Scale consists  of  32 items and contains two subscales: 
Sedative  and Stimulant  (Oliveto  et  al.,  1992).   Participants rated each item using a 
numeric keypad to select one of five options: “Not at All”,  “A Little Bit”,  “Moderately”, 
“Quite A Bit” and “Extremely” (scored numerically from 0 to 4, respectively; maximum 
score =64).
DSST
Participants completed a 2 minute computerized version of the DSST adopted 
from McLeod et al., 1982. The dependent measures for this psychomotor task were trial 
completion rate and accuracy.
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Data Analysis
Triazolam effects were analyzed using repeated-measures ANOVA with triazolam 
dose, menstrual cycle phase and time as factors.  Interactions were evaluated using 
simple-effects analyses.
RESULTS
Drug Discrimination Task
Figure 1.1 presents mean drug-appropriate responding as a function of triazolam 
dose administration during control and test sessions. During the final 5 control sessions, 
which occurred at  different menstrual cycle phases across subjects, drug-appropriate 
responding emerged only after the active dose of triazolam was administered [dose by 
time interaction: F(4, 24) = 14.78, p < .001], and greater than 80% responding occurred 
reliably  on the drug-appropriate option for  all  subjects  beginning at  90 minutes  post 
dose.  During the test phase, active drug-appropriate responding varied as a function of 
menstrual cycle phase [dose x phase interaction: F(12, 72) = 2.13, p = .025], with simple 
effects analysis indicating significant cycle phase effects occurring at the 0.12 mg/70 kg 
test dose [F(9, 27) = 7.90,  p < .001]. During the early follicular phase, three of seven 
subjects identified placebo as triazolam, resulting in intermediate levels of responding 
when averaged across all subjects, but responding was not significantly different from 
that occurring during the mid-luteal phase at this dose.  The 0.06 mg/70 kg dose was 
identified  as placebo during  both  cycle  phases.   The 0.12 mg/70 kg test  dose was 
identified  as  triazolam-like  during  the  mid-luteal  phase,  whereas  during  the  early 
follicular  phase,  responding  was  comparable  to  that  observed  following  placebo 
administration.   The  active  training  dose  of  triazolam  (0.25  mg/70  kg)  engendered 
triazolam-appropriate responding during both menstrual cycle phases.
Adjective Rating Scale
A dose  by  menstrual  cycle  phase interaction  was  detected  on  the  Stimulant 
subscale of the ARS (p ≤ .05), with ratings at the 0.06 mg/70 kg dose showing greater 
decreases  during  the  mid-luteal  phase  relative  to  the  early  follicular  phase  (simple 
effects: p ≤ .05).
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Other Measures
Consistent with previous studies (e.g., Rush et al.,  2000; 1999; Stoops et al., 
2005),  triazolam  engendered  prototypical  sedative  effects  on  many  self-report, 
performance,  and  cardiovascular  measures  (Table  1.2).   Baseline  cardiovascular 
measures  varied  across  cycle  phases (e.g.,  Ounis-Skali  et  al.,  2006),  but  triazolam 
effects were independent of cycle phase across all other measures.
Additional  data  (means and  standard errors  for  each measure  collected)  are 
available in Appendix A.
DISCUSSION
The  results  of  this  study  clearly  demonstrate  that  triazolam  functioned  as  a 
discriminative  stimulus  in  healthy  women  and  that  sensitivity  to  the  discriminative 
stimulus  effects  of  triazolam  was  influenced  by  menstrual  cycle  phase.  The 
discriminative stimulus effects of the 0.12 mg/70 kg test dose were enhanced during the 
mid-luteal phase, compared to the early follicular phase, of the menstrual cycle.  These 
results, along with a growing body of literature, support the hypothesis that progesterone 
modulates the behavioral effects of GABAergic drugs (e.g., Grant et al., 1997, Green et 
al., 1999; Kroboth et al., 1985; McAuley et al., 1995).
Menstrual cycle phase effects were detected with drug discrimination and with 
the stimulant  subscale of  the ARS.  Previous research using drug discrimination with 
nonhuman primates showed enhanced sensitivity to alcohol effects during the mid-luteal 
phase (Grant et al., 1997, Green et al., 1999); however, self-report measures of sedative 
drug effects have not typically changed across menstrual cycle phases in clinical studies 
(e.g., Holdstock & de Wit, 2000; Rukstalis & de Wit, 1999). These data suggest that drug 
discrimination may be more sensitive to menstrual cycle phase modulation of sedative 
drug  effects  than  self-report  measures  alone.   It  is  has  been  suggested  that  drug 
discrimination may be more sensitive to drug action at the receptor level, such that drugs 
with similar pharmacological profiles share similar discriminative effects, while subjective 
effect measures may be more likely to reflect interoceptive cues engendered by non-
pharmacological states (Kelly et al., 2003). As drug discrimination establishes consistent 
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responding in  the presence of  a drug effects,  it  provides formalized pharmacological 
training for each participant, whereas subjective measures rely on participants’ verbal 
history to identify interoceptive drug effects. The discordance between the discriminative 
stimulus and subjective effects of drugs has been reported across several drug classes 
(Preston & Bigelow, 1991; Chait  et  al.,  1986; Kelly et  al.,  2003) and may be in part 
influenced by verbal conditioning history, contingencies associated with responding, or 
training conditions.  
During control sessions, which were scheduled without regard to menstrual cycle 
phase, the 0 mg/70 kg dose engendered consistent responding on the non-drug option. 
Surprisingly,  during  the  early  follicular  phase  of  test  sessions,  placebo  engendered 
triazolam-appropriate responding in three of seven participants.  The potential influence 
of several factors was examined, including the number of days post menses of testing, 
prior drug use history, rate of acquisition of the triazolam discrimination, and menstrual 
cycle phase during control sessions, but none served as a reliable predictor of placebo 
responding during the early follicular phase.  
There were a few notable limitations to the current study. First, although cycle 
phases were determined using the onset of menses and objective measures of ovulation 
among  women  with  regular  menstrual  cycles,  plasma  hormone  levels  were  not 
measured.  The correlations between serum levels of estradiol and progesterone and 
drug response have been demonstrated (White et al, 2002; Justice & de Wit, 2000; de 
Wit & Rukstalis, 1997).  Second, the Sampling and Control Phases of the discrimination 
training were conducted without  regard to menstrual cycle phase.  It  is possible that 
varied hormone levels during sampling and control phases may have influenced either 
rate  of  acquisition  of  the  discrimination  or  results  obtained  during  the  test  phase. 
However, we were unable to identify any factors, related to cycle phase or otherwise, 
that  were  associated  with  individual  differences  in  the  rate  of  acquisition  of  the 
discrimination.   Furthermore,  the  proportion  of  participants  acquiring  the  drug 
discrimination  (7  of  12)  is  comparable  to  that  in  other  triazolam drug  discrimination 
studies (Vansickle & Rush, 2006; Rush et al., 2003; Rush et al., 2000; Kamien et al., 
1997).   Third,  although a within-subject  design was employed,  the sample size  was 
modest,  and the sensitivity of  self-report  and other measures to cycle phase effects 
might have been established with a larger sample. 
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Although this  study provided clear evidence that  the effects of  triazolam vary 
across the menstrual cycle, the relative role of progesterone in this effect is unclear. 
During the early follicular phase, both progesterone and estrogen are at nadir levels. 
During the mid luteal phase, peak levels of progesterone emerge; however, estrogen 
levels are elevated as well. Despite the well-documented evidence of progesterone and 
its  metabolites modulating GABAA activity  through a receptor-based mechanism, this 
study cannot provide conclusive evidence that the interaction observed was exclusively 
mediated by elevated levels of endogenous progesterone.  Therefore, follow-up studies 
were  conducted  to  isolate  and  directly  manipulate  the  effects  of  progesterone  to 
determine if acute progesterone administration modulates the effects of triazolam.
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Table 1.1.  Demographic data from participants who acquired the triazolam 
discrimination and those who were unable to acquire the discrimination.
16
Discriminators (n=7) Non-Discriminators (n=5)
Age 29.86 20.20
Weight (kg) 59.71 70.00
Caffeine (mg/day) 105.58 29.33
Alcohol (drinks/week) 0.53 2.30
Nicotine (cigarettes/day) 10 (n=1) 0.17 (n=1)
Other drug use None reported None reported
Beck 4.29 2.00
MAST 1.29 3.40
ADHD 2.57 3.40
Table 1.2.  Significant F-values of selected measures for which a significant main 
effect or interaction was obtained. No Triazolam x Cycle x Time interactions 
were detected.
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FIGURE 1.1. Average triazolam-appropriate responding as a function of triazolam dose 
and  menstrual  cycle  phase  from  assessments  occurring  between  90  and  150 
minutes post dose.  The left panel displays responding during the Control Phase, 
during which training doses were administered.  Data points represent means (± 
SEM  denoted  by  the  error  bars)  of  seven  subjects.  The  asterisk  indicates  a 
significant difference (p ≤ .05) across cycle phase.
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CHAPTER 3
STUDY 2: Separate and combined effects of progesterone and triazolam in 
       healthy, premenopausal women
INTRODUCTION
Gender differences in drug use and abuse are notable, with greater numbers of 
men reporting non-medical use of drugs than women (SAMHSA, 2009).  However, the 
relative  risk  of  developing  dependence  on  sedative-hypnotic  drugs  (e.g., 
benzodiazepines) appears to be greater for women than men.  After initiating sedative-
hypnotic  drug  use,  women  are  significantly  more  likely  to  develop  problematic  use 
patterns relative to their male counterparts, such that women may be nearly twice as 
likely to develop dependence on these compounds (Kandel et al., 1998; Anthony et al., 
1994).  In addition, women are prescribed sedative-hypnotic compounds at higher rates 
than  men  (Nomura  et  al.,  2006;  Howes  et  al.,  1996;  van  der  Waals  et  al.,  1993; 
Wysowski & Baum, 1991), take the medications longer once prescribed (Geiselmann & 
Linden,  1991), and are more likely to use the medications for non-medical purposes 
(Simoni-Wastila et al., 2004).
Biological  factors,  including  ovarian  hormones,  and  more  specifically  the 
neurosteroid  progesterone  and  its  metabolites,  might  contribute  to  these  gender 
differences  in  sedative-hypnotic  drug  abuse.  Neurosteroids  (e.g.,  progesterone, 
estradiol) are abundantly present in premenopausal women, with plasma concentrations 
varying as a function of menstrual cycle phase.  Research from a variety of sources 
indicates that neurosteroids modulate receptor systems and alter drug effects (McAuley 
et al., 1995; White et al., 2002; Justice et al., 1999; Lynch et al., 2002; Lile et al., 2007). 
Progesterone  and  its  primary  and  derivative  metabolites,  allopregnanolone, 
pregnanolone, and TH-DOC, modulate neurotransmitter activity via genomic and non-
genomic mechanisms.  The non-genomic effects of these neurosteroids include direct 
activation of neuronal membrane-bound receptors and the rapid modulation of several 
neurotransmitter  systems including GABA,  dopamine,  opiate,  glutamate and nicotinic 
acetylcholine systems (Pluchino et al., 2006; Lena et al., 1993).  The best-characterized 
and perhaps most influential of progesterone’s effects are those at the GABAA receptor 
complex.  Sedative-hypnotic  drugs  such  as  the  benzodiazepines  also  produce  their 
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effects,  in  large  part,  via  modulation  of  GABAA receptors.   Allopregnanolone, 
pregnanolone and TH-DOC are ligands at extracellular, steroid-specific recognition sites 
on  GABAA receptors,  with  affinities  that  are  comparable  to  those  of  many 
benzodiazepines  (Paul  &  Purdy,  1992).  In  addition,  these  neurosteroids  dose-
dependently  increase the effects  of  benzodiazepines on  GABA-induced  Cl- currents, 
indicating  that  there  is  a  non-genomic,  receptor-level  interaction  between 
benzodiazepines  and  neurosteroids  (Paul  &  Purdy,  1992;  Bertz  et  al.,  1995).  The 
behavioral  effects  of  these  neurosteroids  also  overlap  with  those  engendered  by 
benzodiazepines  and  include  sedation,  memory  impairment,  anxiolysis,  depression, 
stress  reduction  and  anti-seizure  effects  (Pisu  &  Serra,  2004;  Rhodes  et  al.,  2004; 
Rupprecht, 2003; Schumacher et al., 1989; Schumacher & Robert, 2002).
Because progesterone and its metabolites have a direct action at GABA receptor 
sites,  it  is  hypothesized  that  progesterone  may  potentiate  the  behavioral  effects  of 
GABAergic  drugs.   Preclinical  studies  have  demonstrated  that  the  discriminative 
stimulus effects of ethanol are sensitive to menstrual cycle phase, such that the ethanol 
generalization curve is shifted to the left during the mid-luteal phase of the menstrual 
cycle when progesterone levels surge (Grant et al., 1997, Green et al., 1999).  Similar 
effects  were observed in  healthy,  pre-menopausal  women in  Study 1,  such that  the 
discriminative stimulus effects of triazolam were potentiated during the mid-luteal phase 
relative to the early follicular phase.  Other clinical research examining GABAergic drug 
effects (i.e., triazolam and ethanol) across the menstrual cycle have found little or no 
evidence for cycle modulation of drug effects (Holdstock & de Wit, 2000; Rukstalis & de 
Wit, 1999).
Interactions between neurosteroids and benzodiazepines may be more apparent 
when levels of neurosteroids are directly manipulated.  Examining drug effects across 
the menstrual cycle does not allow for a direct assessment of the effects of progesterone 
because progesterone level increases during the mid-luteal phase coincide with estradiol 
level  increases.   An  alternative  strategy  is  to  assess  the  effects  of  exogenously 
administered progesterone during the early follicular phase when both progesterone and 
estradiol levels are at nadir levels.  When administered as a pre-treatment, exogenous 
oral  micronized  progesterone  enhanced  the  sedative,  memory-impairing  and 
performance  effects  induced  by  intravenous  triazolam  in  post-menopausal  women 
(McAuley  et  al.,  1995).  Those  results  support  the  use  of  this  methodology to  more 
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directly examine interactions between neurosteroids and drug effects. However, there do 
not  appear  to be any studies that  used progesterone-only pretreatments to evaluate 
potential interactions between neurosteroids and sedative-hypnotic drugs in healthy pre-
menopausal women, who might be at increased risk for developing benzodiazepine-use 
disorders.  Thus,  further  study of  the effects  of  GABAergic  drugs following controlled 
administration of progesterone is warranted and should not only provide additional useful 
information regarding progesterone modulation of the GABA-mediated behavioral effects 
of  drugs,  but  also  help  elucidate  gender-specific  sensitivity  to  the  effects  of 
benzodiazepines.  The purpose of the present study is to determine the independent and 
combined subjective and psychomotor effects of progesterone and triazolam in healthy 
adult premenopausal women.
METHOD
Participants
This study used methods similar to those of Study 1 and participant recruitment 
procedures,  medical  screening protocol  and exclusion criteria  were the same across 
studies. Eligibility criteria for this study was slightly different and  included a minimum of 
18 years of age, reports of occasional sedative drug use (e.g., alcohol), and use of an 
oral, hormone-based contraceptive that included a 7 consecutive-day placebo phase.  
Sixteen  participants  were  enrolled  in  the  study.   Five  participants  did  not 
complete the study for reasons unrelated to the protocol and their data are not included 
in  the analyses.   Eleven women (10 Caucasian,  1 African American)  completed  the 
study.  The participants ranged in age from 21 to 26 years (median = 22 years) and in  
weight from 51 to 72.4 kilograms (median = 63 kg; BMI range= 19.2 to 26.3, median = 
22.2).  All participants were non-smokers.  Alcohol use ranged from less than 1 to 7.5 
alcohol drinks per week (median = 3) and caffeine use ranged from 0 to 185 mg of 
caffeine per  day  (median = 80 mg).   One participant  reported nonmedical  use of  a 
prescription stimulant medication (i.e., Adderall) on two occasions in the month prior to 
study participation.   Participants reported no additional  psychoactive drug use in the 
month prior to study participation and no drug use was detected during the study with 
daily urinalysis testing.  Participants were compensated for their participation.
Design
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A double-blind, placebo-controlled, randomized design was used to assess the 
effects  of  three  within-subject  variables,  progesterone  dose  (0,  100  and  200  mg), 
triazolam dose (0.00, 0.12 and 0.25 mg/70 kg), and time (30, 60, 90, 120 and minutes 
after  triazolam  administration,  which  correspond  to  75,  105,  135,  165,  195  after 
progesterone administration), on the subjective, performance and cardiovascular effects 
of triazolam during the early follicular phase of the menstrual cycle (e.g., the placebo 
phase of the oral birth control regimen) when estrogen and progesterone levels are at 
their nadir.
Drugs
Doses  of  progesterone  and  triazolam  were  prepared  by  the  University  of 
Kentucky Investigational Pharmacy.  Progesterone (0, 100, 200 mg; Prometrium) and 
triazolam (0.00, 0.12 and 0.25 mg/70 kg) were prepared in size 00 and 0 distinct opaque 
capsules,  respectively,  each  with  cornstarch filler.   Placebo capsules  contained only 
cornstarch filler.  Both progesterone and triazolam doses were delivered orally.
Schedule
Participants completed one training session prior to the experimental sessions to 
acquaint  them  with  the  study  procedures  and  to  establish  consistent  and  accurate 
performance on computerized behavioral  tasks. This practice session was conducted 
irrespective  of  menstrual  cycle  phase  but  within  one  week  of  the  initiation  of  the 
experimental  sessions.   The subsequent  nine experimental  sessions were conducted 
during the participant’s  placebo phase of  their  oral  birth  control  regimen (e.g.,  early 
follicular phase).   Each permutation of progesterone and triazolam doses was tested 
once in random order.  Each experimental session was 6 hours in length. Participants 
completed  the  study  across  2-4  months  time,  with  each  session  occurring  at 
approximately the same time of day across the study.
Screening and laboratory check in procedures (i.e., drug testing, field sobriety 
test) were identical to those used in Study 1 and were consistent across studies. 
Thirty  minutes  after  progesterone  administration,  participants  consumed  a 
moderate-fat snack to enhance progesterone absorption (Simon et al., 1993; Stanczyk, 
1999).  Triazolam was administered 15 minutes after snack delivery.  Assessments were 
repeated  in  30-minute  intervals  for  3  hours  after  triazolam  administration.   Each 
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assessment  consisted  of  Visual  Analog  (VAS)  and  Adjective  Rating  (ARS)  Scales, 
Addiction  Research  Center  Inventory  (ARCI),  Profile  of  Mood  States  (POMS),  Digit 
Symbol Substitution Task (DSST), Balloon Analog Risk Task (BART) and heart rate and 
blood pressure measurement (Sentry II, NBS Medical, Costa Mesa, CA). Only measures 
that are different form those used in Study 1 are described below.  
Assessment Tasks
VAS
Similar to the version used in Study 1, the scale presented in the current study 
included 32 items, including: Stimulated, Stressed, Sedated, Anxious, Nervous, Light-
Headed,  Sleepy, Sick to Stomach, Shaky, Jittery, Depressed, High,  Euphoric,  Active, 
Alert, Energetic, Drug Effect, Good Drug Effect, Bad Drug Effect, Performance Impaired, 
Performance Improved, Like Drug, and Pay for Drug.
ARCI
The 49-item short form of the true-false inventory (Martin et al.,  1971) yielded 
information on five dimensions: Lysergic Acid Diethylamide (LSD) scale, Amphetamine 
(A) Scale, Benzedrine-Group (BG) Scale, Morphine-Benzedrine Group (MBG) Scale and 
the Pentobarbital, Chlorapromazine, Alcohol Group (PCAG) Scale.
ARS
The Adjective Rating Scale consists  of  32 items and contains two subscales: 
Sedative and Stimulant (Oliveto et al., 1992).  In the present study, only the 16 items 
from  the  Sedative  subscale  were  presented.   Participants  rated  each  item  using  a 
numeric keypad to select one of five options: “Not at All”,  “A Little Bit”,  “Moderately”, 
“Quite A Bit” and “Extremely” (scored numerically from 0 to 4, respectively; maximum 
score =64).
BART
Participants  were  presented  with  20  individual  balloons  in  succession  on  a 
computer screen, as adapted from Lejuez et al., 2002.  Participants clicked a mouse to 
inflate each balloon.  Each inflation increased the balloon earnings counter by $0.01 and 
increased the probability of the next inflation to pop the balloon.  Each balloon would pop 
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after  a  random,  unpredictable  number  of  inflations.  Participants  could  collect  their 
balloon earnings prior  to a balloon popping by clicking on a “Collect  Money” option. 
However,  if  a  balloon  popped,  earnings  from  the  balloon  were  permanently  lost. 
Earnings from each task presentation were recorded and participants were given their 
task earnings from a randomly chosen assessment at  the end of  the session.   The 
dependent measures were number of inflation responses per un-popped balloons, and 
number of balloons popped.
Data Analysis
Drug  effects  were  analyzed  using  repeated-measures  ANCOVA  with 
progesterone dose, triazolam dose and time as factors and baseline assessment prior to 
drug administration serving as a covariate. Significant interactions were evaluated using 
simple-effects analyses.  Because baseline measures were used as covariates,  drug 
effects were identified by a main effect of dose or a dose by time interaction, depending 
on the time course of the drug effect.   Similarly, drug interactions were apparent as 
either a drug by drug interaction, or a drug by drug by time interaction, again depending 
on the time course of the interaction.
RESULTS
Independent  of  progesterone,  triazolam  produced  prototypical  sedative-like 
effects on multiple measures including VAS Sleepy, ARS Sedated and POMS Fatigue 
(Table 2.1).  Figure 2.1 presents VAS ratings of Drug Effect (top row), VAS ratings of 
Sedated  (middle  row)  and  ARCI  PCAG  Scale  ratings  (bottom  row)  as  exemplars. 
Triazolam increased subjective ratings on each scale, as evidenced by a main effect of 
triazolam  and  triazolam  by  time  interaction  (Table  2.1).   Based  on  simple  effects 
analyses, triazolam effects occurred at the high dose of triazolam (0.25 mg/70 kg) 90 
through 150 minutes after dose administration on VAS Drug Effect (Figure 2.1, open 
squares, panels A through C) and ARCI PCAG scale (open squares, panels D through 
F), and occurred 120 through 150 minutes on the VAS Sedated Scale (open squares, 
panels G through I).
Both doses of progesterone also produced sedative-like effects on a profile of 
measures similar to those of triazolam (Table 2.1).  Figure 2.1 (left column) displays the 
time course of progesterone alone on VAS Drug Effect (panel A), VAS Sedated (panel 
D), and ARCI PCAG scale (panel G), with peak effects of progesterone in combination 
24
with  placebo  triazolam  occurring  75  through  105  minutes  after  progesterone 
administration (i.e., 30 through 60 minutes post triazolam administration).
A significant interaction between progesterone and triazolam was also detected 
on  the  sedative-like  measures  of  drug  effect,  including  POMS  Fatigue  (Table  2.1). 
Figure 2.1 (top row) displays the progesterone by triazolam interaction on ratings of VAS 
Drug Effect.   Simple  effects  analysis  indicated significant  progesterone effects  at  all 
doses of triazolam, with increases occurring at  both active doses of  progesterone in 
combination  with  the  moderate  dose  (0.12  mg/70  kg)  of  triazolam  (panel  B)  and 
increases occurring at 200 mg of progesterone in combination with the high dose (0.25 
mg/70 kg) of triazolam (panel C) (p < .05).  Compared to progesterone alone (panel A), 
the combination of progesterone and triazolam extended the duration of and delayed 
peak ratings of VAS Drug Effect (panels B and C).  Significant interactions were not 
detected on ratings of VAS Sedated and ARCI PCAG, but the profile of effects were 
similar to those of VAS Drug Effect,  with increases in occurring when either dose of 
progesterone  was  combined  with  the  moderate  dose  of  triazolam  (0.12  mg/70  kg) 
(panels E and H) and when 200 mg was combined with the high dose of triazolam (0.25 
mg/70 kg) (panels F and I), the peak effects were delayed.   .
Separate  and  combined  effects  of  progesterone  and  triazolam  were  also 
observed on measures that  have typically  considered to be indirect  measures of the 
reinforcing and aversive effects of drugs.  For example, independent of progesterone, 
triazolam increased ratings of VAS Euphoric and High (Table 2.1).  Figure 2.2 displays 
ratings of VAS Good Drug Effect (top row), VAS Bad Drug Effect (middle row) and VAS 
Pay for Drug (bottom row) as representative measures.  Triazolam modified ratings on 
each scale, as evidenced by a main effect of triazolam (Table 2.1).  The high dose of 
triazolam (0.25 mg/70 kg) increased ratings of VAS Good Drug Effect (Figure 2.2, open 
squares, panels A through C) and VAS Bad Drug Effect (open squares, panels D through 
F), and decreased ratings of VAS Pay For Drug (open squares, panels G through I), with 
these effects occurring at 90 through 150 minutes after triazolam administration.
As evidenced by a main effect of progesterone (Table 2.1), progesterone alone 
also  increased  ratings  of  VAS  Good  Drug  Effect  75  through  105  minutes  after 
progesterone administration (Figure 2.2, panel A) and VAS Bad Drug Effect at 105 to 
135 minutes (panel D).  No main effect of progesterone was detected on VAS Pay for 
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Drug (panel G).
A significant  interaction between progesterone and triazolam was detected on 
each measure presented in Figure 2.2.  Simple effects analyses of ratings of VAS Good 
Drug Effect indicated that increases were observed when 100 mg of progesterone was 
combined with the moderate dose of triazolam (Figure 2.2, panel B) and increases also 
occurred when 200 mg of progesterone was combined with the high dose of triazolam 
(panel C) (p <.05).  Simple effect analyses of ratings of VAS Bad Drug Effect indicated 
that  increases  occurred  when  either  dose  of  progesterone  was  combined  with  the 
moderate dose of triazolam (panel E) and when 200 mg of progesterone was combined 
with high dose of triazolam (panel F) (p < .05).  Simple effects analyses of ratings of VAS 
Pay for Drug revealed an interaction primarily related to a small effect of progesterone at 
placebo triazolam (panel G); however increased effects were also observed when 200 
mg of progesterone was combined with the high dose of triazolam (Graph F) (p < .05). 
Similar to the trends observed on measures of sedation (Figure 2.1), the combination of 
progesterone  and  triazolam  delayed  the  peak  effects,  compared  to  the  effects  of 
progesterone alone.
Separate  and  combined  effects  of  progesterone  and  triazolam  were  also 
observed on measures of psychomotor task performance as well as self-evaluations of 
performance acuity  (Table 2.1).   Figure 2.3 presents DSST measures of  Total  Trials 
Completed  (top  row),  and  VAS  ratings  of  Performance  Impaired  (middle  row)  and 
Performance Improved (bottom row).   Main effects of triazolam or a triazolam by time 
interaction were observed on each measure (p < .05).  Simple effects analyses indicated 
that triazolam effects on both DSST Total  Trials (Figure 2.3, open squares, panels A 
through  C)  and  VAS  Performance  Impaired  (open  squares,  panels  D  through  F) 
occurred at highest dose of  triazolam (0.25 mg/70 kg) 90 through 120 minutes after 
triazolam administration (p < .05).  No triazolam by time interaction was detected on VAS 
Performance  Improved,  but  the  time  course  was  similar  to  other  measures  of 
performance, with peak effects occurring 90 and 120 minutes post-dose.
A main  effect  of  progesterone  was  observed  on  VAS Performance  Impaired 
(Table 2.1), with progesterone increasing ratings early in the session (Figure 2.3, panel 
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D).  A main effect of progesterone was also detected on DSST Total Trials (Table 2.1); 
however minimal effects of progesterone were observed in combination with placebo 
triazolam (panel A).
A significant interaction between progesterone and triazolam was also detected 
on each of the measures in Figure 2.3.  Simple effects analyses of DSST Total Trials  
indicated that 200 mg progesterone combined with 0.12 mg/70 kg triazolam significantly 
decreased trial completion (Figure 2.3, panel B) and on associated measures, such as 
number  of  correct  trials  on  the  DSST (p <  .05).   Simple  effect  analyses  indicated 
increases in  VAS Performance Impaired ratings at  both active dose of  progesterone 
combined with 0.12 mg/70 kg triazolam (panel E) and by 200 mg combined with 0.25 
mg/70 kg (panel F) (p < .05).  Simple effects analyses of VAS Performance Improved 
indicated ratings were increased by the combination of 100 mg of progesterone and the 
moderate dose of triazolam (panel H) and by 200 mg combined with the high dose of 
triazolam, although the magnitude of the effect was small (panel I).   Similar to other 
measures (Figure 2.1 and 2.2), progesterone administration delayed the time to the peak 
effects as triazolam dose increased.
Significant  main  effects  of  both  progesterone  and  triazolam,  as  well  as  a 
significant interaction between progesterone and triazolam, were observed on number of 
responses per un-popped balloon on the BART (Table 2.1).  Follow-up testing of the 
progesterone by triazolam interaction indicated an effect of progesterone at each dose of 
triazolam and an effect  of triazolam only at 100 mg dose of progesterone (p < .05). 
Examination of these data indicated significant variability in the number of responses per 
balloon occurring during baseline sessions, with small magnitude increases across time 
following placebo progesterone administration and a small magnitude decrease following 
either 100 or 200 mg progesterone.   This  effect  was particularly evident at the 0.12 
mg/70 kg dose of triazolam.  No differences in number of responses per balloon were 
observed at any assessment, indicating that progesterone and triazolam effects on this 
task  are  related  to  variability  in  performance  as  opposed  to  any  reliable 
neuropharmacological effects of either compound.
Separate  and  combined  effects  of  progesterone  and  triazolam  were  also 
observed on cardiovascular measures (Table 2.1).  Follow up analyses indicated small 
magnitude increases in each cardiovascular measure across time, but no systematic 
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changes due to administration of either drug were observed at any assessment.  These 
trends  indicate  that  statistical  significance  was  related  to  variability  at  baseline 
measurements  as  well  as  across  assessments  and  not  systematically  related  to 
pharmacological modulation of cardiovascular measures.
Additional  data  (means and  standard errors  for  each measure  collected)  are 
available in Appendix B.
DISCUSSION
The present study used subjective, performance and cardiovascular measures to 
evaluate  the  effects  of  exogenous  progesterone,  alone  and  in  combination  with 
triazolam, in healthy, pre-menopausal women.  The results of this study demonstrated 
that both progesterone and triazolam, alone,  produced sedative-like effects,  and that 
their effects in combination were greater than those of either compound in isolation.  In 
addition,  the drug combination also shifted the time course of  triazolam effects,  with 
peak effects occurring later in the session.
Triazolam, when administered alone, engendered prototypical subjective, performance 
and cardiovascular effects, most consistently at the highest dose (0.25 mg/70 kg).  Peak 
behavioral effects of 0.25 mg/70 kg triazolam occurred between 1.5 and 2.5 hours after 
dose  administration,  which  is  consistent  with  previous  reports  (Rush  et  al.,  2003; 
Simpson & Rush, 2002).  Progesterone alone also produced sedative-like effects on a 
variety  of  subjective  effect  measures  at  both  doses,  with  peak  behavioral  effects 
occurring between 1.25 and 1.75 hours after progesterone administration (30 and 60 
minutes post triazolam administration).  The magnitude and time course of these effects 
were somewhat different than have previously been reported.  Sedative-like effects of 
progesterone are typically limited to administration of higher oral doses than were used 
in this study, or to routes of administration with greater bioavailablity (i.e., intramuscular 
administration) (Freeman et al., 1993; Soderpalm et al., 2004; de Wit et al., 2001).  In 
addition,  peak  effects  of  oral  progesterone  have  previously  been  reported  to  occur 
between  2  and  2.5  hours  after  drug  administration  (Sofuoglu,  et  al.,  2001,  2002; 
Chakmakjian & Zachariah, 1987).  The most likely factor contributing to the more rapid 
onset and increased magnitude of  sedative-like effects in the present  study was the 
administration of a moderate-fat snack thirty minutes after progesterone administration, 
as  the  administration  of  a  moderate-fat  meal  has  been  reported  to  increase 
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progesterone  bioavailability  (Simon  et  al.,  1993;  Stanczyk,  1999).   However,  other 
factors,  such  as  participant  characteristics  (i.e.,  participants  in  this  study  were  light 
drinkers, had limited or no previous benzodiazepine exposure, and were taking oral birth 
control), could also have contributed to the pharmacodynamic effects observed in the 
present study.
The  combined  effect  of  progesterone  and  triazolam  resulted  in  enhanced 
subjective, performance and cardiovascular effects, as compared to those of triazolam 
or progesterone in isolation.  The combination of progesterone and triazolam also shifted 
the time course of peak progesterone effects.  When administered alone, progesterone 
effects  were  limited  to  initial  assessments  (1.25  to  1.75  hours  after  progesterone 
administration).  However, when progesterone was combined with either active dose of 
triazolam, the peak effects were shifted to time points in the latter portion of the session 
(135 through 195 minutes after progesterone administration, or 90 through 150 minutes 
after triazolam administration). Generally, both doses of progesterone combined with the 
moderate dose of triazolam (0.12 mg/70 kg) produced an enhanced effect, while only the 
200 mg dose of progesterone produced increased effects at the high dose of triazolam 
(0.25 mg/70 kg). In addition, peak effects of progesterone in combination with the 0.12 
and 0.25 mg/70 kg dose of triazolam occurred at times in which progesterone, alone, 
had minimal subjective, performance or cardiovascular effects.
The  enhanced  magnitude  of  triazolam  effects  occurring  at  times  in  which 
progesterone, alone, had minimal effects and the shifted time course of progesterone 
effects  may  be  associated  with  circulating  levels  of  the  neuroactive  progesterone 
metabolites allopregnanolone and TH-DOC which are GABAA ligands and can produce 
behavioral effects similar to alcohol and benzodiazepines (Lambert et al., 1995, 2009; 
Grant et al., 2008). Although TH-DOC and pregnanolone levels rise after progesterone 
administration,  the  clinical  time course  of  these  hormone derivatives  have  not  been 
established.   After  oral  progesterone  administration,  peak  progesterone  and 
allopregnanolone levels occur at 2 hours, with levels remaining elevated above baseline 
for a total of 5 and 8 hours, respectively (Andréen et al., 2006; Nahoul et al., 1993).  In 
the absence of blood levels of progesterone and its metabolites, the relative impact of 
each neurosteroid is not clear.  However, the time course of these hormones may help 
inform the basis of the enhanced effect of the combination of progesterone and triazolam 
during times when progesterone alone engendered minimal subjective or performance 
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effects (i.e., 135 through 195 minutes after progesterone administration).
Although  progesterone  activity  at  GABAA receptor  complex  is  the  most  well-
characterized  effect,  other  neurotransmitter  systems  may  be  involved  when 
progesterone  is  combined  with  triazolam.   Progesterone  and  its  metabolites  may 
engender  some  effects  via  modulation  of  other  neurotransmitter  systems,  as  these 
neurosteroids  have  been  shown  to  rapidly  modulate  dopamine,  serotonin,  opiate, 
glutamate and nicotinic acetylcholine systems (Pluchino et al., 2006; Lena et al., 1993). 
Further research is necessary to determine the specificity of neurosteroid modulation of 
benzodiazepines.
Overall,  the  combined  effect  of  progesterone  and  triazolam  yielded  rather 
consistent  effects  on  a  variety  of  sedative-like  measures.   However,  seemingly 
incongruent  effects  on  subjective  measures  of  drug  effect  and  performance  ability 
emerged in  this  study.   VAS ratings  of  Good Drug Effect  and  Bad Drug Effect  and 
similarly,  ratings  of  Performance  Impaired  and  Performance  Improved  were 
simultaneously increased after administration of the combination of progesterone and 
both active doses of triazolam.  Many drugs of abuse engender simultaneous positive 
and negative drug effects, and it has been proposed that the balance between these 
opposing  effects  may  determine how readily  a  drug  is  self-administered  (Foltin  and 
Fischman, 1991).  Subjective effect ratings of performance ability and psychomotor task 
performance were also somewhat disparate.  When progesterone was administered in 
isolation, ratings of VAS Performance Impaired increased while DSST Total Trials, an 
objective measure of performance, was not substantially affected.  Triazolam impaired 
DSST task performance, while simultaneously increasing ratings of both performance 
impairment and improvement.  Inconsistencies between self-ratings of performance and 
objective measures of behavior have been previously reported (Marczinski et al, 2008; 
Brumback et al., 2007; Marczinski & Fillmore, 2006; Roache & Griffiths, 1985), although 
it is not clear whether changes in dimensions of performance that were not measured in 
the  present  study  (e.g.,  reaction  time,  response  inhibition,  coordination)  could  have 
influenced participant’s ratings of improved performance.
BART performance was not sensitive to the effects of triazolam or progesterone, 
which is consistent with previous reports that have examined the acute effects of dose 
ranges of other GABAergic drugs, such as diazepam (Reynolds et al., 2004) and alcohol 
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(Reynolds et al., 2006), suggesting that performance on this measure of impulsivity is 
generally  insensitive to the acute effects  of  GABAergic drugs in  healthy participants. 
Similarly,  cardiovascular  activity  was  minimally  affected  by  the  dose  range  of 
progesterone and triazolam tested in the present study, which is also consistent with 
previous studies reporting minimal effects of either progesterone or triazolam (at similar 
doses)  on  cardiovascular  activity  (Sofuoglu  et  al.,  2002,  2004;  Haga  et  al.,  2003; 
Simpson  &  Rush,  2002).   The  present  study  extends  these  previous  results  by 
demonstrating  that  the  combined  effects  of  triazolam  or  progesterone  also  have 
negligible effects on BART performance and cardiovascular activity.
Some limitations to the present study should be noted.  In the current study, both 
active doses of progesterone engendered some sedative-like effects in isolation, and 
generally  only  the  highest  dose  of  triazolam produced  statistically  significant  effects 
compared to placebo.  Future studies should examine progesterone and benzodiazepine 
interactions  with  a  wider  range  of  benzodiazepine  doses  and  include  progesterone 
doses that engender minimal measurable effects when administered in alone.  Another 
limitation to this study was the unexpected discordance of the onset of peak effects of 
progesterone and triazolam, with peak progesterone effects occurring approximately 1 
hour prior to the peak effects of triazolam.  Although the study was designed to examine 
concomitant peak effects, the separate peak of effects of each compound allowed for 
interesting interactions to emerge.   Experimental sessions were conducted only during 
the 7-day placebo phase of participants’ oral contraceptive regimen.  Because the study 
consisted of 9 sessions, it could not be completed during one week, which resulted in 
some sessions being separated by several  weeks.  However,  this design allowed for 
sessions  to  occur  when  progesterone  and  estradiol  were  at  nadir  levels,  permitting 
controlled manipulation  of  progesterone levels.  A similar  design was used to assess 
hormonal  modulation  of  the  discriminative  stimulus  effects  of  the  stimulant  drug  d-
amphetamine  in  women  (Lile  et  al.,  2007).   Separating  sessions  could  also  have 
reduced the likelihood that tolerance or sensitization would occur.
These results, along with a growing body of literature, support the hypothesis that 
progesterone modulates the behavioral effects of GABAergic drugs (e.g., Grant et al., 
1997; Green et al., 1999; Kroboth et al., 1985; McAuley et al., 1995).  In addition, these 
data suggest that progesterone may be one factor among many that contributes to the 
gender  differences  observed  in  benzodiazepine  misuse,  whereby  women  are  at  an 
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elevated risk of developing dependence on benzodiazepine medications compared to 
men. Taken together, these studies should inform potential strategies in gender-specific 
prevention and treatment of sedative drug use.
Although an interaction between progesterone and triazolam was observed in 
this study, this interaction occurred after the effects of progesterone had dissipated.  It is 
unclear if  the magnitude of  this interaction would be enhanced if  simultaneous peak 
effects were generated, or if the interaction was due to progesterone metabolites, which 
emerge after  the  peak effects  of  progesterone.   To more  thoroughly  investigate  the 
mechanisms of this interaction, the final study will adjust the timing of progesterone and 
triazolam administration  so  that  simultaneous  peak  effects  emerge.  In  addition,  this 
study  will  also  complement  the  results  of  Studies  1  and  2  as  it  incorporates drug 
discrimination methodology to more thoroughly assess the neuropharmacological effects 
of progesterone, alone and combination with triazolam. 
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Table 2.1.  F-values of selected measures for which a significant main effect or 
interaction was obtained.
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FIGURE 2.1. Mean ratings of VAS Drug Effect (top panel), VAS Sedated (middle panel) 
and ARCI PCAG Scale (bottom panel) as a function of triazolam dose, 
progesterone dose and time following triazolam/progesterone administration.  Data 
points represent means (±S.E.M. denoted by the error bars) of 11 participants. 
Different y-axis scales are used across the three measures.  
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Figure 2.2. Mean ratings of VAS Good Drug Effect (top panel), VAS Bad Drug Effect 
(middle panel) and VAS Pay for Drug (bottom panel) as a function of triazolam 
dose, progesterone dose and time following triazolam/progesterone administration. 
Data points represent means (±S.E.M. denoted by the error bars) of 11 
participants. Different y-axis scales are used across the three measures. 
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Figure 2.3. Mean trials completed on DSST Total Trials (top panel), ratings of VAS 
Performance Impaired (middle panel) and VAS Performance Improved (bottom 
panel) as a function of triazolam dose, progesterone dose and time following 
triazolam/progesterone administration.  Data points represent means (±S.E.M. 
denoted by the error bars) of 11 participants. Different y-axis scales are used 
across the three measures. 
36
CHAPTER 4
STUDY 3: Progesterone modulation of the discriminative stimulus, subjective and 
performance effects of triazolam in healthy, pre-menopausal women
INTRODUCTION
Neurosteroids (e.g., progesterone, allopregnanolone) are abundantly present in 
premenopausal women, with plasma concentrations varying as a function of menstrual 
cycle  phase.   Both  pre-clinical  and  clinical  research  indicates  that  neurosteroids 
modulate receptor systems and alter drug effects (McAuley et al., 1995; White et al., 
2002; Justice et al., 1999; Lynch et al., 2002; Lile et al., 2007).  Progesterone and its 
metabolites, allopregnanolone, TH-DOC, and pregnanolone, have non-genomic effects 
at  binding  sites  on  neuronal  membrane-bound  receptors  and  also  modulate  several 
neurotransmitter  systems including GABA,  dopamine,  opiate,  glutamate and nicotinic 
acetylcholine systems (Pluchino et al., 2006; Lena et al., 1993).  In particular, both in 
vitro and in vivo studies have shown evidence that progesterone and its metabolites 
modulate activity at the GABAA receptor complex, with these neurosteroids acting as 
ligands at  extracellular,  steroid-specific recognition sites on GABAA receptors,  having 
affinities that are comparable to those of many benzodiazepines (Paul & Purdy, 1992). 
The  neuroactive  metabolites  also  dose-dependently  increase  the  effects  of 
benzodiazepines on GABA-induced Cl- currents, indicating that there is a non-genomic, 
receptor-level interaction between benzodiazepines and neurosteroids in vitro (Paul & 
Purdy, 1992; Bertz et al., 1995).
Pre-clinical  research has indicated that  menstrual  cycle  phase modulates the 
some of the effects of GABAergic drugs.  The discriminative stimulus effects of ethanol 
are enhanced during the mid-luteal phase, when endogenous progesterone levels are 
elevated  (Grant  et  al.,  1997,  Green  et  al.,  1999).   Study  1  demonstrated  cycle 
modulation of benzodiazepine effects in pre-menopausal women, with potentiation of the 
discriminative stimulus effects of triazolam occurring during the mid-luteal phase (relative 
to the early follicular phase).  However, there is little or no evidence for cycle modulation 
of  the subjective and performance effects  of  GABAergic  drug effects  (i.e.,  triazolam, 
ethanol)  in  pre-menopausal  women (Holdstock & de Wit,  2000;  Rukstalis  & de Wit, 
1999).  One potential  reason for the inconsistent  clinical results could be due to the 
sensitivity of drug discrimination methodology, as cycle modulation of the discriminative 
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stimulus effects of drugs may be more sensitive to neuropharmacological manipulations 
than subjective or performance measures (Kelly et al., 2003).
Examining  drug  effects  across  the  cycle  provides  information  about  how the 
endogenous  hormonal  milieu  modulates  drug  effects,  but  does  not  provide  a  direct 
measure  of  the  relative  effect  of  a  particular  hormone,  due  to  several  hormones 
simultaneously  fluctuating  throughout  the  cycle.   For  example,  during the mid-luteal 
phase, progesterone levels increase, but estradiol levels are elevated as well, making it 
difficult to discern the effect of progesterone alone.  To determine the independent effect 
of progesterone and its primary metabolites, the effects of GABAergic drugs have also 
been examined  after  exogenous progesterone administration.   Administration  of  oral 
micronized progesterone enhanced the sedative, memory and performance effects of 
intravenous triazolam in post-menopausal women (McAuley et al., 1995).  In addition, 
the  results  of  Study  2  indicated  that  oral  micronized  progesterone  enhanced  the 
subjective and performance effects of oral triazolam in healthy, premenopausal women 
during the early follicular phase, when endogenous progesterone and estrogen are at 
nadir levels. These studies provide evidence that acute administration of progesterone 
enhances  some  behavioral  effects  of  benzodiazepines.   However,  in  both  of  these 
studies, the onset and peak effects of progesterone occurred prior to the peak effects of 
triazolam and interactions between progesterone and triazolam were detected after peak 
progesterone effects had occurred.  The asynchronous time courses for progesterone 
and triazolam suggest that their interactions might have be underestimated, or driven 
predominantly by neuroactive progesterone metabolites, specifically allopregnanolone, 
which remains elevated several hours after oral progesterone levels peak.
The  purpose  of  the  present  study  was  to  determine  the  independent  and 
combined discriminative stimulus, subjective and psychomotor effects of progesterone 
and triazolam in healthy adult  pre-menopausal  women using a dosing schedule that 
should allow for peak drug and hormone effects to occur concurrently. This arrangement 
allows for a close examination of the potential interaction between the two compounds 
and  provides  information  regarding  the  hormonal  constituents  that  may  drive  the 
interaction (i.e., the parent hormone progesterone vs. the progesterone metabolites that 
occur several hours after progesterone levels peak). Drug discrimination methodology 
was  chosen  to  more  precisely  examine  the  neuropharmacological  effects  of 
progesterone, alone and combination with triazolam, as drug discrimination has been 
shown  to  be  an  effective  tool  in  examining  pharmacological  changes  mediated  by 
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receptor-based interactions (Colpaert, 1999; Kelly et al., 2003).
METHOD
Participants
Recruiting  procedures,  medical  screening  protocols  and  inclusion/exclusion 
criteria were identical to those used in Study 2. 
Fourteen participants were enrolled in the study.   Three participants withdrew 
from the study for reasons unrelated to the study protocol, two were discontinued from 
the study because they did not acquire the drug discrimination; data from these five 
participants were not included in the data analyses.  Nine participants (8 Caucasian, 1 
African American) completed the study.  The participants ranged in age from 18 to 30 
years (median = 22 years) and in weight from 55 to 93 kilograms (median = 65.95 kg;  
BMI range = 21 to 31, median = 22.1).  All participants were non-smokers.  Alcohol use 
ranged from less than 1 to 8 alcohol drinks per week (median = 4) and caffeine use 
ranged from 0 to 200 mg of caffeine per day (median = 80 mg).  Participants reported no 
psychoactive drug use in the month prior to study participation and no drug use was 
detected during the study with daily urinalysis testing.  Urine screens for pregnancy were 
also  negative  throughout  participation.  Participants  were  compensated  for  their 
participation.
Design
A double-blind, placebo-controlled, randomized design was used to assess the 
effects of three within-subject variables: progesterone dose (0 and 100mg), triazolam 
dose (training doses: 0.00 and 0.25 mg/70 kg, test doses: 0.06 and 0.12 mg/70 kg), and 
time (assessments occurring prior to and 30, 60, 90, 120 and 150 minutes after dose 
administration) on the discriminative stimulus and other behavioral effects of triazolam 
during the early follicular phase of the menstrual cycle (i.e., placebo phase of the oral 
birth control regimen), when estrogen and progesterone levels are at their nadir.
The results of Study 2 indicated that oral progesterone, when administered with a 
moderate-fat  snack,  produced peak behavioral  effects  75 to 105 minutes  post-dose, 
while oral triazolam effects occur 90 to 150 minutes post dose.  In an effort to examine 
the  concurrent  peak  effects  of  these  medications,  progesterone  and  triazolam were 
administered simultaneously.
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Drugs
Doses  of  progesterone  and  triazolam  were  prepared  by  the  University  of 
Kentucky Investigational Pharmacy.  Progesterone (0 and 100 mg; Prometrium®) and 
triazolam (0.00, 0.06, 0.12 and 0.25 mg/70 kg) were prepared in size 00 and 0 distinct 
opaque capsules, respectively, each with cornstarch filler.  Placebo capsules contained 
only cornstarch filler.  Both progesterone and triazolam doses were delivered orally.
Schedule
Participants completed one training session prior to the experimental sessions to 
acquaint  them  to  the  study  procedures  and  to  establish  consistent  and  accurate 
performance on computerized behavioral  tasks. This practice session was conducted 
irrespective  of  menstrual  cycle  phase  but  within  one  week  of  the  initiation  of  the 
experimental sessions.
After  a  baseline  assessment,  progesterone  and  triazolam  were  administered 
simultaneously.   Fifteen  minutes  after  drug  administration,  participants  consumed  a 
moderate-fat snack to enhance progesterone absorption (Simon et al., 1993; Stanczyk, 
1999).  Assessments  were  repeated  at  30-minute  intervals  for  3  hours  after  drug 
administration, and consisted of the Drug Discrimination Task (post-dose assessments 
only),  Visual  Analog  (VAS)  and  Adjective  Rating  Scales  (ARS),  Addiction  Research 
Center Inventory (ARCI), Profile of Mood States (POMS), Digit Symbol Substitution Task 
(DSST),  Balloon  Analog  Risk  Task  (BART)  and  heart  rate  and  blood  pressure 
measurement (Sentry II, NBS Medical, Costa Mesa, CA).  Only the drug discrimination 
procedure will be described here, as it is somewhat different than the procedure used in 
Study 1.  The VAS, ARS, ARCI, POMS, DSST and BART are exactly the same as those 
described in Study 2.   
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Assessment Tasks
Drug discrimination task
During this task, two circles labeled with a letter code (e.g., “Drug A” and “Not Drug 
A”)  were  displayed  on  the  computer  screen,  each  associated  with  a  training  dose 
condition.  Counters were displayed directly beneath the circles.  A mouse controlled the 
location of a cursor on the screen, and mouse button clicks with a cursor positioned on a 
circle increased the counter associated with that circle according to a Fixed Interval (FI) 
1-s schedule.  The cursor could alternate across the circles without any consequence 
under the FI schedule (i.e., no changeover delay).  Up to 60 points could be allocated 
across  the  two  options.   The  dependent  variable  for  this  task  was  the  percent  of 
responding on the active drug-appropriate option.
The drug discrimination task in this study was slightly different than that used in 
Study 1.  This study established the discrimination using two options labeled ‘Drug’ and 
‘Not Drug,’ rather than ‘Drug A’ and ‘Drug B.’ The Drug v. Not Drug procedure has been 
reported  to  establish  discrimination  behavior  that  is  more  consistent  with  the 
pharmacological  activity  and subjective  effects  of  medications than other  procedures 
(e.g.,  the Drug A v.  Drug B task used in  study  1)  (Preston & Bigelow,  2000;  1994; 
Preston et al., 1992).
Sampling, control and testing phases were presented during the study.  Sampling 
and control phases were conducted without regard to menstrual cycle phase.  The test 
phase was scheduled to coincide with the early follicular phase of the menstrual cycle 
(i.e., placebo phase of the oral birth control regimen), when endogenous levels of both 
progesterone and estrogen are at nadir levels. Participants completed the Test Phase 
across 2 to 4 consecutive menstrual cycle phases.
Sampling Phase
The sampling phase consisted of two experimental sessions.  On each of the two 
sessions, participants were informed that the medication she was receiving was ‘Drug A’ 
(0.25 mg/70 kg triazolam and 0 mg progesterone). A unique letter code (i.e., ‘Drug A’) 
was  used  for  each  participant.   The  following  written  instructions  were  available  to 
participants throughout this phase:
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"This is Drug A.  During the next two days, you will receive Drug A.  Pay close 
attention to how Drug A makes you feel. In the future, you will not be told which dose you 
have received and you will have to decide whether or not you received Drug A. During 
the next two days your earnings from the Drug Identification Task will be based on how 
many points you allocate to the Drug A option.  Please do your best to allocate all the 
points to the Drug A option."
Control Phase
The control phase was used to determine whether participants had acquired the 
drug discrimination.  Daily schedules during the control phase were identical to those 
during the sampling phase, with the exception that the participants were blind to the 
identity of the administered drug (i.e., Drug A, or Not Drug A) until the end of the session. 
The training dose of triazolam (0.25 mg/70 kg, Drug A) or placebo (Not Drug A), and 
placebo progesterone, were administered randomly under double-blind conditions, with 
each  triazolam  dose  presented  at  least  twice,  but  the  same  dose  was  never 
administered on more than three consecutive days.  The criterion for acquisition of drug 
discrimination was ≥ 80% of responses allocated to the drug-appropriate option during 
the  last  assessment  of  the  session  (150  minutes  post-dose)  for  five  consecutive 
sessions.   If  the  acquisition  criterion  was not  met  in  12 sessions,  participants  were 
dismissed from the study.  Participants who met criteria did so within 5 to 12 sessions. 
Performance  payment  was  contingent  on  discrimination  responding,  with  10  cents 
earned for each correct response (i.e., points) allocated to the option associated with the 
dose  administered  that  day.  The  following  written  instructions  were  available  to 
participants:
“Today we will not tell you whether you received Drug A or Not Drug A. Instead, you 
will have to decide whether you received Drug A or Not Drug A. If you think you received 
Drug A, and in fact you did receive Drug A, you can earn extra money by responding on 
the button labeled Drug A. If you do not think you received Drug A, and in fact you did 
not receive Drug A, you can earn extra money by responding on the button labeled Not 
Drug A. For example, if you feel that you did not receive any drug today, you should 
respond on the button labeled Not Drug A. Similarly, if  you think that you received a 
drug, but it feels different than Drug A, you should respond on the button labeled Not 
Drug A. You can change your drug identifications throughout today's session based on 
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what you think at the time.
At the end of some sessions, the computer will present a screen that will tell you if 
you received Drug A or Not Drug A. The number of points that you accumulated on the 
correct button will then be converted to money and you will be told how much bonus 
money you earned during today's session. At the end of some sessions, we may not be 
able to tell you whether you received Drug A or Not Drug A. On the days that we cannot 
tell whether you, your bonus earnings will be the average of the amount you earn on 
days in which we can tell you that you received Drug A or Not Drug A.”
Test Phase
During the Test Phase, dose-response generalization functions were established 
for  triazolam (0.00,  0.06,  0.12,  and  0.25  mg/70  kg)  alone  and  in  combination  with 
progesterone (0.00 and 100 mg). One permutation of progesterone (0 and 100 mg) and 
triazolam  (0.00,  0.06,  0.12,  and  0.25  mg/70  kg)  was  administered  during  each 
experimental session in random order, for a total of 8 sessions. On days that participants 
received a training dose (i.e., 0.00 or 0.25 mg/70 kg oral triazolam with 0 mg sublingual  
progesterone),  participants  received  feedback  regarding  the  accuracy  of  their 
performance at the end of the session and payment was contingent upon accuracy (as 
in the Control Phase).  The instructions presented during the Control Phase were also 
available during Test Phase sessions.
Data Analysis
Drug  effects  were  analyzed  using  repeated-measures  ANOVA with  triazolam 
dose, progesterone dose and time as factors.  Interactions were evaluated using simple-
effects analyses.
RESULTS
Drug Discrimination
Figure 3.1 presents mean drug-appropriate responding as a function of triazolam 
and  progesterone  dose  during  control  and  test  sessions.   During  control  sessions, 
participants met the drug discrimination acquisition criterion in a mean of 7 sessions 
(range of  5 to 12,  median = 8).   Across the final  5 control  sessions,  all  participants 
emitted approximately  0 % and 99% drug appropriate responding 150 minutes  after 
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placebo and active drug administration,  respectively.   During the test phase, training 
dose conditions (0.00 and 0.25 mg/70 kg) engendered 11% and 100% triazolam-like 
responding.  The test doses (0.06 and 0.12 mg/70 kg) produced intermediate triazolam-
like  responding,  approximately  30%  and  50%,  respectively.   This  intermediate 
responding was due to averaging data from participants identifying the dose as either 
drug-like or non-drug-like (i.e., quantal responding by individual subjects).  Progesterone 
alone engendered 27% drug-like responding, resulting from two participants identifying 
100 mg progesterone as drug-like. Progesterone in combination with triazolam did not 
modify drug discrimination responding at any triazolam dose.
Subjective Effects
Triazolam alone produced prototypical sedative-like effects on multiple self-report 
measures, including increases in ARS Sedation, VAS Sedated, Sleepy and Performance 
Impaired, POMS Fatigue and ARCI PCAG Scale (Table 3.1). In addition, a main effect of 
triazolam or  an  interaction  of  triazolam and  time was also  observed  for  VAS Light-
Headed,  High, Energetic and Drug Effect  and POMS Vigor,  and Arousal (Table 3.1). 
Figure 3.2 presents VAS ratings of Sedated (top row), Performance Impaired (middle 
row) and Drug Effect (bottom row) as exemplars. As illustrated in Figure 3.2, peak effects 
of triazolam occurred 60 through 90 minutes after administration on each measure.
Independent  of  triazolam, progesterone also engendered sedative-like effects, 
including VAS Sedated, Sleepy and Performance Impaired (Table 3.1).  In addition,  a 
main  effect  of  progesterone  or  an  interaction  of  progesterone  and  time  was  also 
observed for VAS ratings of Drug Effect and Good Drug Effect (Table 3.1). Peak effects 
of progesterone also occurred 60 to 90 minutes after administration on each measure.
The combination  of  progesterone and triazolam engendered small  magnitude 
increases in subjective effects, compared to either dose alone (Figure 3.2). The effects 
of  progesterone  on  the  response  to  triazolam appeared  to  be  additive;  that  is,  the 
magnitude of the increase in subject ratings associated with dose combinations was not 
greater than that of progesterone alone.  In addition, progesterone delayed the time at 
which peak effects occurred for the high dose of triazolam (0.25 mg/70 kg; 90 through 
150 minutes).
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Performance Effects
Triazolam  produced  prototypical  sedative-like  effects  on  measures  of 
psychomotor task performance, with a main effect of triazolam detected on DSST trial 
rate and accuracy (Table 3.1).  Independent of triazolam, progesterone decreased trial 
accuracy  (Table  3.1).   Similar  to  what  was  observed  for  the  combined  effects  of 
progesterone and triazolam on subjective effects, small magnitude additive effects were 
apparent for trial accuracy.
No independent or combined effects of progesterone or triazolam were observed 
on BART performance.
Cardiovascular Effects
Significant triazolam and progesterone effects were observed on diastolic blood 
pressure (Table 3.1); however, these effects were small in magnitude (approximately 5 
mm  Hg)  and  limited  to  specific  points  in  time.   It  is  unlikely  that  these  changes 
represented systematic drug effects or drug interactions.
Additional  data  (means and  standard errors  for  each measure  collected)  are 
available in Appendix C.
DISCUSSION
The present  study  used  drug discrimination  and subjective,  performance and 
cardiovascular  measures  to  examine  the  effects  of  progesterone,  alone  and  in 
combination with triazolam in healthy, pre-menopausal women. Consistent with previous 
studies, triazolam alone engendered a broad range of sedative-like effects in a dose-
related manner, with peak effects occurring 60 to 90 minutes post dose (Greenblatt et 
al., 2005; Rush et al., 2003; Simpson & Rush, 2002; Rush & Ali, 1999).  Progesterone 
alone produced small magnitude increases in sedative-like measures with a similar time 
course.  The combination of progesterone and triazolam engendered additive effects on 
subjective and performance effects and delayed the time at which the peak effects of the 
0.25 mg/70 kg dose of triazolam occurred.  Triazolam functioned as a discriminative 
stimulus,  but  progesterone  did  not  consistently  substitute  for  or  modulate  the 
discriminative stimulus effects of triazolam
One aim of this study was to examine the effects of progesterone and triazolam 
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under conditions in which the peak effects for the hormone and drug occurred at similar 
times.   To  accomplish  this  goal,  progesterone  and  triazolam  were  administered 
simultaneously, as Study 2 has indicated that peak effects emerge at similar times.  This 
approach was successful with peak effects of both progesterone and triazolam occurring 
60 to 90 minutes post-dose. Worth mentioning is that self-reported and performance 
effects of progesterone alone are not typically observed unless significantly higher oral 
doses  (600  to  1200  mg)  or  routes  of  administration  with  greater  bioavailablity  (i.e., 
intramuscular administration) are administered (Freeman et al., 1993; Soderpalm et al., 
2004; de Wit et al., 2001; van der Meer et al., 1982).  These results replicate the results 
of Study 2 in which doses of progesterone (100 and 200 mg PO) also increased ratings 
of  several  sedative-like  measures  and  engendered  decreases  in  psychomotor  task 
performance.  The effects of progesterone may have been enhanced in that study, and 
the present  study,  due to the administration of  moderate-fat  snack 15 minutes  after 
progesterone  administration,  which  has  been  reported  to  increase  progesterone 
bioavailability (Simon et al., 1993; Stanczyk, 1999).
A second aim of the study was to examine the neuropharmacological effects of 
progesterone,  alone  and  in  combination  with  triazolam,  using  a  drug  discrimination 
methodology. Progesterone alone did not substitute for the training dose of triazolam, 
and  concurrent  progesterone  administration  did  not  alter  the  discriminative  stimulus 
effects of triazolam. These data do not suggest a common receptor mechanism of action 
for progesterone and triazolam.  It is possible that the sedative effects of progesterone 
were not mediated by a GABAergic mechanism, although in vitro and pre-clinical in vivo 
research has clearly documented GABAergic interactions between neurosteroids and 
GABAergic agents, progesterone and its metabolites have also been shown to modulate 
multiple receptor systems, including dopamine, serotonin, opiate, glutamate and nicotinic 
acetylcholine receptor systems (Pluchino et al., 2006; Lena et al., 1993).  However, other 
interpretations  are  also  plausible.   First,  only  a  single,  relatively  small  dose  of 
progesterone was tested.  Progesterone may have engendered small, GABA-mediated 
increases in the effects of the low doses of  triazolam that were below the threshold 
necessary  to  produce  reliable  drug-like  responding  on  the  drug  discrimination  task. 
Second, it is possible that progesterone modulation of triazolam effects is dependent on 
triazolam dose (Green et al., 1999).  There is some evidence to support this possibility in 
that progesterone effects on the highest triazolam dose (i.e., a shift in the time course of 
the peak effects of the 0.25 mg/70 kg training dose) were distinct from those occurring at 
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lower  doses.   Because  this  shift  was  limited  to  the  training  dose  of  triazolam,  this 
enhancement would not have been detected due to the ceiling effect imposed by the 
drug  discrimination  procedure.  Third,  it  is  possible  that  progesterone  modulation  of 
triazolam effects is dependent on progesterone metabolites, rather than progesterone 
per se (Lundgren et al., 2003; Majewska et al., 1986).  The shift in peak effects of the 
highest  triazolam  dose  occurred  after  progesterone  effects  had  dissipated  and 
progesterone  metabolites,  such  as  allopregnanolone,  would  be  expected  to  peak, 
supporting this possibility.  Specifically,  allopregnanolone levels  increase 2 hours after 
oral progesterone administration and remain elevated for up to 8 hours (Andréen et al., 
2006;  Nahoul  et  al.,  1993).   The  interactions  between  progesterone  and  triazolam 
documented in Study 2 and in previous studies also occurred at times corresponding to 
the emergence of progesterone metabolites (McAuley et al., 1995).
The drug discrimination results of this study were not consistent with those of 
Study 1 which demonstrated that the discriminative stimulus effects of triazolam were 
potentiated during the mid luteal phase, when endogenous progesterone levels were 
elevated.  Several factors could have contributed to these disparate results, including the 
presence  of  other  neurosteroids,  the  duration  of  exposure  to  neurosteroids  and 
progesterone delivery.  The current study used exogenous, oral progesterone, while the 
previous study relied on naturally occurring changes in endogenous progesterone levels 
across  the  menstrual  cycle.  The  progesterone  dose  used  in  the  current  study  was 
selected to engender systemic progesterone levels comparable to those of the mid luteal 
phase (Simon et al., 1993; Stanczyk, 1999).  However, during the mid luteal phase, there 
is  a  broader  milieu  of  hormones  of  present,  including  estrogen  and  progesterone 
metabolites, such as allopregnanolone (Genazzani et al., 1998).  The relative influence 
of  estrogen  on  GABAergic  drug  effect  is  not  clear.  However,  allopregnanolone  is 
neuroactive and a ligand at the GABAA receptor, and several cell culture and preclinical 
studies  have  identified  allopregnanolone  as  a  key  component  in  the  hormone-
benzodiazepine interaction at the GABAA receptor (Lambert et al., 2009; Paul & Purdy, 
1992).  The duration of exposure to neurosteroids may also have influenced sensitivity to 
the discriminative stimulus effects of triazolam across studies.  During the luteal phase of 
the  menstrual  cycle,  progesterone  and  allopregnanolone  levels  remain  elevated  for 
approximately 10 days (Genazzani et al., 1998).  This cycle-related chronic exposure to 
neurosteroids may engender genomic-based increases in sensitivity to benzodiazepines 
(Smith et al., 1998), which may have influenced the mid luteal phase enhancement of 
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the discriminative  stimulus effects of  triazolam.   In  addition,  the chronic  exposure of 
progesterone and its metabolites create steady blood levels of neurosteroids, whereas 
blood levels after exogenous progesterone administration begin to decline 2 hours after 
administration (Genazzani et al., 1998; Stanczyk, 1999).  This difference in onset and 
duration  of  action may also help  explain  why exogenous progesterone engenders a 
drug-like  effect,  while  similar  levels  of  endogenous  progesterone  do  not  typically 
engender subjective effects.  A third factor that could have resulted in differential effects 
across  studies  is  progesterone  delivery.   In  the  current  study,  progesterone  was 
administered  orally,  whereas  the  previous  study  relied  on  endogenous  changes  in 
progesterone  levels  across  the menstrual  cycle.   Several  studies  have  documented 
inconsistent  absorption  of  progesterone  associated  with  oral  dosing,  with  a  40  fold 
magnitude  of  differences  in  absorption  occurring  across  individuals  (McAuley  et  al., 
1996; Simon et al., 1993).
This study examined the effects of progesterone, alone and in combination with 
triazolam  under  conditions  in  which  the  time  course  of  progesterone  and  triazolam 
effects were concordant.  Prototypical sedative-like effects of triazolam were observed, 
and consistent with our previous study, progesterone alone also engendered statistically 
significant increases in sedative-like effects on self-report and performance measures. 
Progesterone and triazolam engendered additive effects on self-report and performance 
measures when combined; however, progesterone did not substitute for the triazolam 
discriminative stimulus, and concurrent progesterone administration had no effect on the 
discriminative stimulus effects of triazolam.  Future studies examining a wider range of 
progesterone doses and progesterone metabolites in combination with both higher and 
lower training doses of triazolam and longer-acting benzodiazepines would be useful to 
further examine receptor-based interactions of progesterone and benzodiazepines.
48
Table 3.1.  F-values of selected measures for which a significant main effect or 
interaction was obtained. No Triazolam x Progesterone or Triazolam x 
Progesterone x Time interactions were detected.
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Figure 3.1. Mean triazolam-appropriate responding as a function of triazolam dose and 
progesterone condition from assessments occurring at 150 minutes post-dose 
during the control and test phases. Data points represent means of nine 
participants. Uni-directional error bars represent 1 S.E.M.
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Figure 3.2. Mean ratings of VAS Drug Sedated (top row), VAS Performance Impaired 
(middle  row)  and VAS Drug Effect  (bottom row)  as a function of  progesterone 
dose,  triazolam dose  and  time following  drug  administration.   The  left  column 
presents triazolam effects after 0 mg progesterone and the right column presents 
triazolam effects after 100 mg progesterone.  Error bars omitted for clarity.
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CHAPTER 5
GENERAL DISCUSSION
The purpose  of  this  series  of  studies  was to  determine  whether  the  ovarian 
hormone progesterone modulates the behavioral effects of the sedative drug triazolam 
using human laboratory methodologies.  The behavioral effects of triazolam and other 
benzodiazepines  are  associated  with  the  drugs’  positive  modulation  of  the  GABAA 
receptor  complex  (Lelas  et  al.,  2002;  Licata  et  al.,  2009;  Rush  et  al.,  1998). 
Benzodiazepines function as discriminative stimuli in human models (Rush et al, 2003; 
Vansickel  et  al,  2006;  Kelly  et  al.,  2003;  Oliveto et al.,  1992)  and the discriminative 
stimulus effects of benzodiazepines are sensitive to GABAA modulation (McMahon & 
France, 2005a; 2005b; Lelas et al., 2000).  The sensitivity of this paradigm allows for the 
examination of the GABA-modulating effects of progesterone, which also exerts potent 
effects on behavior via modulation of GABAA receptors (Rupprecht, 2003; Lambert et al., 
2009; Bertz et al., 1995; Paul & Purdy, 1992; Majewska, 1992; Majewska et al., 1986).
Overall,  the  results  of  these  studies  indicate  that  progesterone  and  its 
neuroactive metabolites modulate the effects of triazolam.  Changes in menstrual cycle 
associated with increases in progesterone and exogenous progesterone administration 
modified the effects of triazolam in pre-menopausal women.  In addition,  exogenous 
progesterone, independent of triazolam, produced behaviorally active effects at lower 
doses than have been previously been reported (Freeman et al., 1993; Soderpalm et al., 
2004; de Wit et al., 2001; van der Meer et al., 1982). When concordant peak effects of 
progesterone  and  triazolam  were  examined,  the  combination  of  progesterone  and 
triazolam  engendered  additive  effects  on  subjective  and  performance  effects  and 
delayed the time at  which the peak effects  of  the 0.25 mg/70 kg dose of  triazolam 
occurred;  however  progesterone  did  not  consistently  substitute  for  or  modulate  the 
discriminative stimulus effects of triazolam. These effects suggest that the effects of the 
parent  hormone  progesterone  do  not  appear  to  be  associated  with  the  same 
neuropharmacological mechanisms of action as triazolam. 
OVERVIEW OF STUDY 1
The first study examined the discriminative stimulus, subjective, performance and 
cardiovascular  effects  of  triazolam  across  two  phases  of  the  menstrual  cycle  to 
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determine  if  the  hormonal  milieu  unique  to  each  cycle  phase  would  differentially 
contribute to premenopausal women’s sensitivity to triazolam effects.  The results of the 
study clearly indicated that cycle phase modulated triazolam effects, such that during the 
early follicular phase, the discriminative stimulus effects of all test doses (0.00, 0.06 and 
0.12 mg/70 kg) were identified as placebo-like, while only the training dose (0.25 mg/70 
kg) was identified as drug-like.  In contrast, during the mid luteal phase, only placebo 
and the low test dose (0.06 mg/70 kg) engendered placebo-like responding, whereas the 
moderate  dose  (0.12  mg/70  kg)  and  the  training  dose  were  identified  as  drug-like. 
These data suggest that  sensitivity to the discriminative stimulus effects of triazolam 
were modulated by menstrual cycle phase.  However, the relative role of progesterone in 
this interaction is not completely clear.  Progesterone and other female sex hormones 
are  at  nadir  levels  during  the  early  follicular  phase.   During  the  mid  luteal  phase, 
progesterone levels are at their peak, but estrogen levels are also elevated throughout 
this cycle phase.  Therefore, even though there is very strong evidence from in vitro and 
pre-clinical in vivo research to suggest that progesterone is a neuroactive steroid with 
activity  at  the  GABAA receptor,  this  study  did not  convincingly  demonstrate  that  the 
triazolam modulation observed was directly caused by elevations in progesterone. 
OVERVIEW OF STUDY 2
Therefore,  follow-up  studies  were  conducted  to  further  examine  the  potential 
interaction between progesterone and triazolam.  The goal of the second study was to 
isolate and directly manipulate progesterone to determine if  the changes in triazolam 
effects observed previously during the mid-luteal phase were related to progesterone in 
a  dose-dependent  manner.   The  interactions  between exogenous  progesterone  and 
benzodiazepines had not previously been examined, so it was important to test a range 
of  doses of both progesterone and triazolam to determine whether interactions were 
dose-dependent.  As such, the second study examined the subjective, performance and 
cardiovascular  effects  of  a  range  of  exogenous  progesterone  doses,  alone  and  in 
combination with a dose range of triazolam.  The results of this study demonstrated that 
both progesterone and triazolam, alone, produced sedative-like effects on subjective and 
performance  measures.   In  addition,  the  combination  of  progesterone and  triazolam 
produced effects that  were greater than those of  either compound in isolation.   The 
results of this study build on those of the previous study, indicating that progesterone 
alone, had significant effects on behavior at  doses thought to engender blood levels 
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occurring  during  the  mid-luteal  phase  of  the  menstrual  cycle,  and  enhanced  the 
behavioral  effects of triazolam.  The onset of peak effects and duration of effects of 
progesterone, alone, were most consistent with the time course of the parent compound, 
progesterone; whereas interactions with triazolam occurred later in time, and were likely 
associated with increasing levels of progesterone metabolites.  
However,  even though the results of  this study indicated an interaction effect 
between progesterone and triazolam, due to the timing of dose administration, the peak 
effects  of  progesterone and triazolam did not  occur  simultaneously.   The interaction 
between progesterone and triazolam occurred after the effects of progesterone alone 
had dissipated.  The time course of this interaction indicates that this study may not have 
captured  the  potential  magnitude  of  the  interaction  that  may  have  occurred  if  the 
simultaneous peak effects of progesterone and triazolam were examined.  Furthermore, 
it was not clear from these results the degree to which progesterone metabolites were 
involved in the interaction.
OVERVIEW OF STUDY 3
Therefore,  the  final  study  in  this  series  attempted to  examine the interaction 
between progesterone and triazolam under conditions in which the time course of the 
onset and peak effects of the two compounds were relatively concurrent.  In addition, 
this  study  implemented  drug  discrimination  methodology  to  examine  whether 
progesterone  and  triazolam  share  discriminative  stimulus  effects  and  whether 
progesterone administration alters the sensitivity of the discriminative stimulus effects of 
triazolam in order to further elucidate neuropharmacological mechanisms of action. 
Consistent with the results of Study 1, triazolam functioned as a discriminative 
stimulus  and  engendered  prototypical  sedative-like  effects  on  subjective  and 
performance measures.   Replicating the effects of  Study 2,  progesterone alone also 
produced sedative-like effects on subjective and performance measures.  However, in 
contrast to Study 2, this study examined the simultaneous peak effects of progesterone 
and triazolam.  While additive effects of progesterone and triazolam were observed on 
several  measures,  no  evidence  for  pharmacological  interactions  was  obtained.   In 
addition, progesterone did not substitute for or modify the discriminative stimulus effects 
of  triazolam,  suggesting  that  progesterone  and  triazolam  do  not  share  a  common 
receptor mechanism.  
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The  additive-like  effects  of  progesterone  and  triazolam  were  detected  on 
subjective and performance measures, with the most notable effects occurring at the 
moderate  and  high  dose  of  triazolam  (0.12  and  0.25  mg/70  kg).  Furthermore, 
progesterone shifted the time course of the effects of this dose to the right.  Although no 
interaction was observed, the progesterone-induced shift in time course was similar to 
the effects observed in Study 2, suggesting that effects that are separate form the acute 
effects of the parent hormone (e.g., production of progesterone metabolites) may be the 
driving factor in the modulation of the behavioral effects of triazolam.  
The  results  of  these  studies  suggest  that  progesterone  and  its  metabolites 
modulate  the  behavioral  effects  of  triazolam.   This  series  of  studies  used  drug 
discrimination to examine neuropharmacological mechanisms of action.  The available 
evidence  suggests  that  the  behavioral  effects  of  progesterone,  independent  of  its 
primary metabolites,  may occur through receptor mechanisms that  are different  from 
those  of  triazolam.   Progesterone  has  been  shown  to  modulate  several  receptor 
systems, including serotonin (5-HT3), dopamine, nicotinic acetylcholine, NMDA, sigma, 
and oxytocin (Bullock et al, 1997; Wu et al., 1990; Rupprecht, 2003).  It is unclear from 
existing studies the degree to which any of these neurotransmitter systems are involved 
in the behavioral effects of progesterone.  However, a key component in the receptor 
based hormone-benzodiazepine interaction may be progesterone metabolites.  Several 
studies  have  demonstrated  that  neuroactive  progesterone  metabolites,  including 
allopregnanolone, pregnanolone and TH-DOC, are ligands at the GABAA receptor, and 
several  cell  culture  and  preclinical  studies  have  identified  these  neurosteroids  as  a 
driving factor of the modulatory effects of hormones at the GABAA receptor (Lambert et 
al.,  2009; Bertz et al.,  1995; Paul & Purdy, 1992; Majewska, 1992; Majewska et  al., 
1986).  The effects of neuroactive progesterone metabolites may have contributed to mid 
luteal phase potentiation of triazolam effects in Study 1, as levels of allopregnanolone 
are elevated for approximately 10 days during the mid luteal phase (Genazzani et al.,  
1998).  In  addition,  the  effects  of  progesterone  metabolites  may  have  also  have 
contributed to the effects  observed in Study 2, as the interaction effects occurred at 
times when progesterone metabolites emerge. Future studies will be required to more 
fully elucidate mechanisms associated with progesterone’s behavioral effects and the 
potential role of GABA as a mechanism through with progesterone metabolites might 
modulate triazolam effects.
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LIMITATIONS
There were several limitations to these studies that warrant mentioning.  First, in 
Studies 1 and 3 the discriminative stimulus effects of triazolam were established without 
respect to menstrual cycle phase. Sample and control sessions were conducted during 
times when endogenous neurosteroids were at various levels,  creating the possibility 
that the magnitude of the of the discriminative stimulus was variable throughout training. 
Although this may have occurred, the data do not indicate that cycle phase affected the 
rate  at  which  drug  discrimination  was  acquired  or  the  degree  of  sensitivity  to 
progesterone/cycle phase modulation in the test phase; however these studies were not 
powered to examine this factor.  Future research should examine if sample and control 
sessions conducted during the mid luteal phase influence the degree of sensitivity to test 
doses across the cycle.     
A notable limitation in Studies 2 and 3 was the use of a limited dose range of 
progesterone.  An ideal dose range would have included a wider range of doses.  The 
lowest  dose of  progesterone (100 mg),  used in  both studies,  produced sedative-like 
effects on subjective and performance measures.  Although much higher oral doses (600 
to 1200 mg) and different routes of administration (e.g., intravenous and intramuscular) 
that  generate  higher  blood  levels  of  progesterone  have  been  shown  to  increase 
subjective reports of sedation and fatigue (Soderpalm et al., 2004; de Wit et al., 2001; 
Freeman et al., 1992; van der Meer et al., 1982), 100 or 200 mg oral progesterone had 
not engendered sedative-like effects in previous studies (Evans & Foltin, 2006; Sofuoglu 
et  al,  2001;  2002).   A  moderate-fat  meal  administered  shortly  after  progesterone 
administration had been shown to increase oral progesterone absorption (Simon et al., 
1993;  Stanczyk,  1999;  de  Lignières,  1999),  and  may  have  increased  behavioral 
sensitivity  to  these  doses.   Nonetheless,  testing  a  full  dose  response  curve  of 
progesterone,  including  sub-threshold  doses,  would  have  provided a  more  complete 
assessment of the pharmacological interactions of progesterone and triazolam. 
A limited dose range of triazolam was also used in each study.  In particular, 
Study 2 tested only two active doses of triazolam, both of which showed an interaction 
with progesterone.  Testing a sub-threshold dose (e.g., 0.06 mg/70 kg) would have been 
useful  to  determine  if  progesterone  could  modulate  a  lower  dose  of  triazolam.  In 
addition, Study 3 may have benefited from a lower training dose of triazolam. Consistent 
drug-like responding only occurred in the presence of the training dose (0.25 mg/70 kg). 
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Perhaps if a lower training dose had been used (i.e., 0.12 mg/70 kg), sensitivity to lower 
doses of triazolam may have occurred, thereby allowing for the detection of more subtle 
drug effects,  particularly  the effects  of  progesterone and progesterone modulation of 
drug effects.  Alternatively, it may have been useful to include a higher training dose of 
triazolam as well. Progesterone enhanced and shifted the time course of the 0.25 mg/70 
kg triazolam dose to the right. However, since this dose also served as the training dose, 
a ceiling effect limited the possibility of detecting any progesterone enhancement of this 
dose.   A higher  triazolam training  dose  would  support  more  precise  assessment  of 
progesterone effects on the 0.25 mg/70 kg dose.  
The timing of the progesterone and triazolam doses in Studies 2 and 3 produced 
somewhat different effects.  In Study 2, progesterone was administered thirty minutes 
prior  to  triazolam  administration,  which  positioned  the  peak  effects  of  triazolam  to 
coincide with the peak effects of progesterone metabolites, and an interaction effect was 
observed.   In  contrast,  in  Study  3,  progesterone  and  triazolam  were  administered 
simultaneously,  which produced concurrent  peak effects  of  triazolam and the  parent 
hormone  progesterone,  and  no  interaction  was  observed.   Future  studies  should 
examine the discriminative stimulus effects of concordant peak effects of triazolam and 
progesterone  metabolites  to  determine  if  the  presence  of  these  metabolites  would 
modulate the discriminative stimulus effects of triazolam, which may more thoroughly 
address  whether  there  are  common  receptor-based  mechanisms  of  action  between 
progesterone metabolites and triazolam. 
Another limitation of these studies was the lack of pharmacokinetic data.  Blood 
levels of triazolam, progesterone, and progesterone metabolites would have provided 
valuable information regarding the accuracy of menstrual cycle phase determinations, 
the time course of progesterone and its metabolites, the degree to which progesterone 
was absorbed, and the degree to which triazolam pharmacokinetics were altered in the 
presence  of  progesterone  and  its  metabolites.   Future  studies  should  examine  the 
manner  in  which blood levels  of  progesterone and its  metabolites correlate with the 
sensitivity  to  triazolam,  both  across  the  cycle  and  after  exogenous  progesterone 
administration.  
In addition, the population for each study was limited to pre-menopausal adult 
women.  Moreover, in Studies 2 and 3, only women taking certain forms of oral birth 
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control  (e.g.,  formulations containing a 7 day placebo phase) were included.  These 
populations have had chronic exposure to progesterone, either through oral birth control 
regimens or through the mid luteal phase of the menstrual cycle.  Given that the effects 
of repeated exposure to progesterone have been shown to change cellular signaling and 
developmental  brain  structure and function,  it  would be interesting to test  a broader 
range of  study  populations to further  understand the biological  underpinnings of  the 
hormone-benzodiazepine interaction. 
Another limitation was that sample sizes were limited in each study.  Although 
within subject design allows for detection of drug effects with relatively few participants 
and significant effects of both progesterone and triazolam were observed across studies, 
a larger sample size may have increased the ability to detect subtle drug interactions 
and/or individual differences in the sensitivity to progesterone and/or triazolam. 
Another factor that may have influenced these results is the metabolic interaction 
between  progesterone  and  triazolam.   Pre-clinical  research  has  indicated  that 
GABAergic  drugs such as benzodiazepines and ethanol  (as well  as  non-GABAergic 
medications such as atypical antipsychotics) induce the production of progesterone and 
its metabolites (Aouad et al., 2009; Barbaccia, 2004).  However, it is not clear to what 
degree this neurosteroid increase results in changes in drug effects. 
Lastly,  it  is  unclear  the  degree  to  which  the  results  of  these  studies  were 
influenced by the genomic effects of neurosteroids.  Although the non-genomic, receptor 
mediated effects of progesterone are well documented, neurosteroids also have effects 
on genomic processes that  could alter  drug effects.   For example,  rapid  changes in 
blood levels of neurosteroids can alter the degree of gene expression for the α4 GABAA 
subunit.   Rapid  decreases  in  allopregnanolone  increase  gene  expression,  while 
increases  in  allopregnanolone  decrease  gene  expression  for  the  α4 GABAA subunit 
(Rupprecht, 2003; Smith et al., 1998; Grobin & Morrow, 2000).  Pre-clinical models (both 
in  vitro  and  in  vivo)  suggest  that  expression  of  the  α4 subunit  influences  relative 
sensitivity to benzodiazepines, with increased gene transcription leading to decreased 
sensitivity to benzodiazepines and decreased gene expression increasing sensitivity to 
benzodiazepines (Smith et al., 1998; Grobin & Morrow, 2000).  Although the time course 
of these genomic effects in humans is unclear, pre-clinical models have demonstrated 
changes  in  GABAA-mediated  seizure  susceptibility  24  hours  after  neurosteroid 
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manipulations (Smith et al., 1998).  Additional research is necessary to determine the the 
time course of genomic modulation of GABAA receptor composition in humans. 
IMPLICATIONS
Despite these limitations, these series of studies established that progesterone 
plays a role in  the behavioral  effects  of triazolam.  To build  on these results,  future 
research should further examine the mechanism of action of progesterone at the GABAA 
receptor.  Although the behavioral effects of neurosteroids are thought to result from their 
action at  steroid-specific site on the GABAA receptor,  this  effect  has been difficult  to 
establish,  as  there  are  no competitive  antagonists  available  that  block  the action  of 
GABAA modulators that act at steroid-specific binding sites or to block the metabolism of 
progesterone,  thereby  allowing  for  the  independent  examination  of  the  effects  of 
progesterone  and  its  metabolites.   However,  pre-clinical  research  examining  the 
discriminative stimulus effects of neurosteroids, benzodiazepines and negative GABAA 
modulators  provide  evidence  for  a  separate  binding  site  for  neurosteroids  and 
benzodiazepines  at  the  GABAA  receptor.   For  example,  pre-clinical  models  have 
demonstrated that pregnanolone, a neuroactive progesterone metabolite, substitutes for 
the  discriminative  stimulus  effects  of  midazolam;  however  certain  negative  GABAA 
modulators (β-CCE and β-CCM) block this substitution while leaving the discriminative 
stimulus  effects  of  midazolam  intact.   Alternatively,  other  antagonists/negative 
modulators (flumazenil,  Ro-1545-13) leave pregnanolone substitution intact, but block 
the discriminative stimulus effects of midazolam (McMahon & France, 2005b; McMahon 
et  al.,  2001).   This  selective  blockage  of  neurosteroid  and  benzodiazepine  effects 
indicates that although their mechanisms of action at the GABAA receptor are similar (as 
evidenced  by  the  substitution  profile),  the  exact  receptor-level  mechanisms  are 
distinguishable and likely occur through slightly different mechanisms.  Future research 
should examine the discriminative  stimulus effects  of  allopregnanolone,  alone and in 
combination  with  a  benzodiazepine  in  women  and  determine  if  negative  GABAA 
modulators act in a similar manner to selectively block the discriminative stimulus effects 
of each compound, in order to further clarify the neurobiological basis of the interaction 
in humans. 
Although  the  pre-clinical  research  has  suggested  GABAergic  mechanism  for 
neurosteroids,  the  data  from  these  studies,  specifically  Study  3,  indicate  that 
progesterone effects were not exclusively mediated by its action at the GABAA receptor. 
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The neurobiological basis of the sedative-like effects of progesterone are unclear, as 
progesterone engendered subjective and performance effects, but did not modulate or 
substitute for the discriminative stimulus effects of triazolam.  As progesterone has also 
been shown to modulate several other neurotransmitter systems (Bullock et al, 1997; 
Wu et al., 1990; Rupprecht, 2003), future research should examine the degree to which 
progesterone  substitutes  for  the  discriminative  stimulus  effects  of  drugs  acting  at 
serotonin  (5-HT3),  dopamine,  nicotinic  acetylcholine,  NMDA,  sigma,  and  oxytocin 
receptors.  Alternatively, applying medications that act as antagonists at these receptors, 
as  well  as  selective  negative  GABAA modulators,  in  combination  with  progesterone, 
could  also  help  to  determine  the  neurobiological  mechanisms  that  contribute  to  its 
behavioral effects.  
Taken together,  the results  of  these studies have clinical  importance,  as they 
demonstrate that drug effects can be influenced by ovarian hormones.  This information 
is  important  when  considering  women’s  health,  as  the  effects  of  centrally  acting 
medications may not have static effects across the menstrual cycle, during adolescence, 
or  during  menopause,  as  these  all  reflect  times  when  hormone  levels  are  rapidly 
changing.  Knowledge of this effect has led to cycle-based modifications in GABAergic 
medication regimens for women being treated for epilepsy (Reddy, 2009; Herzog et al., 
2009; Bäckström, 1976).  In addition, doses of certain types of anaesthesia medications 
are  also  titrated based on levels  of  endogenous neurosteroids  (Erden et  al.,  2005). 
Future research should determine if  dose modifications might be necessary for other 
GABAergic medications as well.
Importantly, additional research is also necessary to determine if menstrual cycle 
changes influence drug abuse liability in women, as it  is not known if  the reinforcing 
effects of certain drugs may change as a function of menstrual cycle phase.  Variation in 
levels  of  endogenous  neurosteroids,  both  within  and  between  individuals,  may  also 
occasion individual differences in the effects of drugs of abuse. Rapidly increasing levels 
of  neurosteroids  (i.e.,  beginning of  the  luteal  phase,  during female  adolescence),  or 
abrupt  declines  in  neurosteroid  levels  (i.e.,  late  luteal  phase,  peri-menopause  and 
menopause)  may  enhance  or  attenuate  acute  pharmacological  effects,  thereby 
potentially  altering the functional  effects  of  drugs.   Recognizing the degree to which 
hormone variations influence drug effects may help identify gender differences in drug 
abuse liability. 
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Hormonal  modulation  of  drug  effects  may  be  an  important  factor  in  men’s 
sensitivity to drug effects as well.  Although hormonal milieu is not typically thought to 
contribute  differences  in  acute  drug  effects  in  men,  there  are  data  suggesting  that 
exogenous neurosteroids have similar subjective effects in men and women and similar 
discriminative  stimulus  effects  in  male  and  female  animals  (Grant  et  al.,  2008; 
Söderpalm  et  al.,  2004).   It  is  not  clear  if  an  interaction  between  exogenous 
neurosteroids and GABAergic  drugs would occur in  men, but  future research should 
examine this possibility, as it would provide insight into the mechanisms that occasion 
the interaction and would clarify if developmental brain structure unique to each sex or if 
chronic exposure to neuroactive steroids (via the menstrual cycle phase) are necessary 
mediators  in  the  interaction.  This  information  would  also  inform  men’s  health  and 
susceptibility  to drug use.   For example, it  is  unclear the degree to which men with 
elevated levels of endogenous neurosteroids (occurring through natural variations or in 
disease states) may display sensitivity to GABAergic drug effects.  
The manner in which progesterone interacts with GABAergic medications in a 
variety of populations becomes increasingly important as progesterone becomes more 
popular as a prescribed therapeutic.  Progesterone is currently prescribed to women for 
hormone  replacement  therapy,  infertility,  amenorrhea  and  epilepsy  (Mahmud,  2009; 
Check, 2009; Whitehead et al., 1990; Reddy & Rogawski, 2009).  In addition, clinical 
trials  have  been  conducted  using  chronic  progesterone  therapy  as  a 
pharmacotherapeutic for the treatment of cocaine abuse in men (Sofuoglu et al., 2007). 
Current  clinical  trials  are  also  being  conducted  to  determine  if  very  large  doses  of 
intravenous progesterone can decrease the neuronal damage associated with traumatic 
brain injury (Wright et al., 2007).  Endogenous levels of neurosteroids are also taken into 
account when formulating drug regimens for women who are diagnosed with epilepsy, 
specifically catamenial epilepsy, a condition in which hormone levels are associated with 
risk  of  seizure.   Neurosteroids  act  as  anti-epileptics  and  rapid  decreases  in  these 
hormones  decrease  seizure  threshold  (Biagini  et  al.,  2010).   Doses  of  anti-epileptic 
medications are often adjusted to accommodate fluctuations of endogenous hormones, 
with increases in medication doses occurring during times when progesterone levels are 
minimal (follicular phase, late luteal phase) to reduce the possibility of seizures (Biagini 
et  al.,  2010).   In  addition,  new therapies  are  being  developed  in  which  exogenous 
neurosteroids  (progesterone,  allopregnanolone  and  synthetic  derivates  of  these 
hormones) are administered to help control the frequency of catamenial seizures (Reddy 
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& Rogawski, 2009). Information regarding the degree to which progesterone modulates 
GABAergic  function  in  both  men  and  women  and  the  subsequent  interaction  with 
benzodiazepine  and  barbiturate  medications  and  alcohol  may  become  increasingly 
important as these lines of treatment develop. 
Taken  together,  data  from  these  and  similar  studies  will  be  helpful  in  the 
identification  of  individual  differences in  drug effects  and will  assist  in  formulating of 
gender-specific prevention or treatment techniques.
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